Maturitas

Pieter van Keep memorial lecture: menopause - a modern perspective from a controversial history
pp. 1-1(1)
Author: Utian W.H.

Clinical medicine and clinical trials: reflections on a shotgun marriage
pp. 1-1(1)
Author: Bush T.L.

Estrogen replacement and progression or regression of coronary atherosclerosis
pp. 1-1(1)
Author: Herrington D.M.

A European trial on secondary prevention of cardiovascular disease
pp. 2-2(1)
Author: Schenck-Gustafsson K.

The Women's Health Initiative Clinical Trial and observational study
pp. 2-2(1)
Author: Johnson S.

What we have learned about menopause from epidemiological studies
pp. 2-2(1)
Author: McKinlay S.M.

The role of menopause clinics:
pp. 2-2(1)
Author: Smith M.

A psychological approach to management of the menopause
pp. 3-3(1)
Author: Collins A.

Lifestyle approach to management of the menopause
pp. 3-3(1)
Authors: Guthrie J.R.; Dennerstein L.; Dudley E.C.; Burger H.G.; Hopper J.L.; Green A.; Morse C.

An Asian perspective of the menopause
pp. 3-3(1)
Author: Punyahotra S.

Oestrogen and bone cells
pp. 3-3(1)
Authors: Stern P.H.; Tarjan G.; Sanders J.

Bone structure and function in relation to aging and the menopause
pp. 4-4(1)
Author: Mosekilde L.

Clinical aspects of oestrogens and osteoporosis
pp. 4-4(1)
Author: Eriksen E.F.

Other hormones acting on osteoporosis
pp. 4-4(1)
Author: Lindsay R.

The politics of menopause
pp. 4-4(1)
Author: Albery N.

Extragenital effects of hormones
pp. 5-5(1)
Author: Metka M.M.

Role of hormones in human breast development: the menopausal breast
pp. 5-5(1)
Authors: Russo J.; Russo I.H.

The development of a new strategy to prevent diseases of the menopause in postmenopausal women
pp. 5-5(1)
Authors: Jordan V.C.; Lurie R.H.

Hormonal control of cell proliferation in the breast and breast cancer
pp. 5-5(1)
Author: Musgrove E.A.

Hormone replacement therapy (HRT) and breast cancer
pp. 6-6(1)
Author: Hulka B.S.

Progestogen use and breast cancer
pp. 6-6(1)
Author: Sitruk-Ware R.

Hormonal activity in the endometrium
pp. 6-7(2)
Author: Salamonsen L.A.

Ultrasound and the endometrium in postmenopausal women
pp. 7-7(1)
Authors: Grimwade J.C.; Farrell E.A.; Murkies A.L.

Biology of endometrium
pp. 7-7(1)
Author: Rutanen E.-M.

Clinical implications for the endometrium of hormone replacement therapy
pp. 7-7(1)
Author: Pickar J.

Unresolved issues in endometrial cancer and postmenopausal hormone therapy
pp. 8-8(1)
Authors: Weiss N.S.; Beresford S.A.A.; Voigt L.F.; Green P.K.; Shapiro J.A.

Androgens and bone function
pp. 8-8(1)
Author: Davis S.

Androgens during the female lifespan
pp. 8-8(1)
Authors: Buckler H.M.; Robertson W.R.

The use of androgens in the postmenopause-evidence from clinical studies
pp. 8-8(1)
Author: Sherwin B.B.

The media and menopause
pp. 9-9(1)
Author: McCarthy W.

Menopausal medicine under difficult conditions
pp. 9-9(1)
Author: Wasti S.

Menopausal medicine under difficult conditions: the Philippine experience
pp. 9-9(1)
Author: Jalbuena J.R.

Menopausal medicine under difficult conditions
pp. 10-10(1)
Author: Moskovic T.

Neuroendocrine changes and climaterium
pp. 10-10(1)
Authors: Genazzani A.R.; Stomati M.; Rubino S.; Bersi C.; Spinetti A.; Salvestroni C.; Luisi M.; Petraglia F.

Hormones and depression
pp. 10-10(1)
Author: Studd J.W.W.

Hormones and libido
pp. 11-11(1)
Author: Graziottin A.

Tachyphylaxis: a novel approach to management
pp. 11-11(1)
Authors: Wilson A.; Eden J.

Phytoestrogens
pp. 12-12(1)
Authors: Hughes C.L.; Cline J.M.; Williams J.K.; Anthony M.A.; Clarkson T.B.

Oestrogens and dementia
pp. 12-12(1)
Author: Henderson V.

Epidemiology of phyto-oestrogens, cancer and other diseases
pp. 12-12(1)
Authors: Griffiths K.; Morton M.S.

Phytoestrogens from biochemistry to prevention of cancer and other diseases
pp. 12-13(2)
Author: Adlercreutz H.

Prepubertal genistein exposure suppresses mammary cancer and enhances gland differentiation in rats
pp. 13-13(1)
Author: Lamartiniere C.A.

Effect of soy on menopausal symptoms
pp. 13-13(1)
Author: Wilcox G.

Effects of hormonal steroids on brain cells
pp. 13-14(2)
Authors: Garcia-Segura L.M.; Femandez-Galaz C.; Chowen J.A.; Naftolin F.

The effects of estrogen on primate brain circuitry
pp. 14-14(1)
Authors: Naftolin F.; Horvath T.; Garcia-Segura L.M.

Neurosteroids: new roles
pp. 14-14(1)
Author: Baulieu E.E.

Estrogen treatment for senile dementia-Alzheimer's type
pp. 15-15(1)
Authors: Honjo H.; Urabe M.; Iwasa K.; Okubo T.; Tsuchiya H.; Kikuchi N.; Hayashi M.; Hayashi K.

Sex hormones and chronic neurological disorders
pp. 15-15(1)
Author: Somerville E.R.

Hormone replacement therapy (HRT) in diabetes
pp. 15-15(1)
Author: Stevenson J.C.

The menopause, oestrogens and arthritis
pp. 15-15(1)
Author: Spector T.D.

HRT following myocardial infarct, thrombosis & hypertension
pp. 16-16(1)
Authors: Pines A.; Ayalon D.

Menopause transition
pp. 16-16(1)
Author: Morse C.A.

New delivery systems for hormone replacement therapy
pp. 17-17(1)
Author: Fraser I.S.

The consequences of longevity
pp. 17-17(1)
Author: Lachowsky M.

Factors determining androgen levels in aging males
pp. 17-18(2)
Authors: Vermeulen A.; Kaufman J.M.

The benefits and risks of androgen therapy in the aging male
pp. 18-18(1)
Author: Gooren L.J.G.

Adrenal and androgen synthesis in the aging male
pp. 18-18(1)
Author: Carlstrom K.

Cellular mechanisms of action for estrogen in cardio protection
pp. 18-19(2)
Author: Gorodeski G.I.

Effects of HRT on lipids and lipoprotein metabolism
pp. 19-19(1)
Author: de Melo N.R.

Cardiovascular effects of sex steroids
pp. 19-19(1)
Author: Collins P.

Do progestogens attenuate CVS benefits of oestrogens?
pp. 20-20(1)
Author: Goran S.

A review of the problem of compliance
pp. 20-20(1)
Author: Whitehead M.I.

How can compliance be improved in a general practice setting?
pp. 20-20(1)
Author: Roberts P.J.

Womens knowledge of the menopause and HRT and their sources of information
pp. 20-21(2)
Author: Godfree V.A.

Improving HRT compliance during the next decade
pp. 21-21(1)
Author: MacLennan A.H.

Alternative managements to HRT
pp. 21-21(1)
Author: Aso T.

The 1996 who report on the menopause: its implications for research in the clinical, epidemiological and social sciences
pp. 22-22(1)
Authors: Burger H.; Kaufert P.

Clinical aspects of patient identification
pp. 23-23(1)
Author: Delmas P.D.

Non-hormonal treatment for postmenopausal osteoporosis: the role of bisphosphonates
pp. 23-23(1)
Author: Fleisch H.

Alendronate prevents vertebral and clinical fractures in women with existing vertebral fractures: results of the fracture intervention trial.
pp. 23-24(2)
Authors: Karpf D.; Cummings S.; Black D.; Thompson D.

In vitro and in vivo effects of estrogens on prostacyclin and thromboxane and on other vasoactive compounds
pp. 24-24(1)
Authors: Mueck A.O.; Seeger H.; Lippert T.H.

Introduction to vascular biology
pp. 24-24(1)
Author: Celermajer D.

In vitro and in vivo effects of estrogen on nitric oxide and the endothelium
pp. 24-24(1)
Author: Collins P.

Cardiac hemodynamics, menopause and HRT
pp. 25-25(1)
Author: Pines A.

Peripheral vascular changes
pp. 25-25(1)
Author: Cooper A.

Post-menopausal bleeding - the view from the clinic
pp. 25-25(1)
Author: Studd J.

Evaluation of the effects of HRT on the endometrium - the view from the microscope
pp. 25-25(1)
Author: Bergeron C.

Evaluation of the endometrium by ultrasound the view from the screen
pp. 26-26(1)
Author: Hanggi W.

Livial (tibolone) and the specific endometrial response - the view from recent clinical studies
pp. 26-26(1)
Author: Bennink H.C.

Combination continuous therapy - what is the optimal (MPA) dose? Structure of the study
pp. 26-26(1)
Author: Smith H.

Efficacy of ogen/provera regimens
pp. 26-26(1)
Authors: The Ogen Provera Study Group; Baber R.

Combination continuous therapy - what is the optimal MPA dose? Effect on bleeding profiles and endometrial histology
pp. 27-27(1)
Author: Webster M.

Combination continuous therapy - effect on lipid profiles
pp. 27-27(1)
Author: Silberberg S.

Continuous oestrone sulphate and medroxyprogesterone acetate hormone replacement therapy - a study of bone density over 2 years
pp. 27-27(1)
Authors: Nand S.L.; Wren B.G.

Side effects - compliance
pp. 28-28(1)
Author: O'Connor V.

The new definition of osteoporosis and its implications for bone mass measurement in women
pp. 28-28(1)
Author: Delmas P.D.

Prevention of osteoporosis with estrogens, its analogues and progestogens: What is new?
pp. 28-29(2)
Author: Purdie D.W.

Alternatives to hormone replacement therapy: antiresorptive therapy (bisphosphonates and calcitonin)
pp. 29-29(1)
Author: Seeman E.

Alternatives to HRT: what is the role of calcium and vitamin D?
pp. 29-30(2)
Author: Ringe J.D.

Metabolic changes induced by peroral and percutaneous estrogen therapy
pp. 30-30(1)
Authors: Kesaniemi Y.A.; Karjalainen A.H.; Heikkinen J.; Savolainen M.J.; Backstrom A.-C.; Salinto M.

Haemostasis and HRT
pp. 30-30(1)
Author: Kroon U.-B.

Age, estrogens and cognitive function
pp. 30-30(1)
Author: Erkkola R.

Divigel/Sandrena - clinical benefits
pp. 31-31(1)
Author: Viitanen A.T.

Introduction to discussion of urogenital ageing and its treatment
pp. 32-32(1)
Author: Nachtigall L.E.

Urogenital ageing - a hidden problem
pp. 32-32(1)
Author: Goran S.

The female perspective: women's attitudes towards urogenital ageing
pp. 32-32(1)
Author: Wright H.J.

Educational efforts towards better recognition of urogenital ageing
pp. 32-32(1)
Author: Doren M.

The clinical platform for Estring
pp. 33-33(1)
Author: Bachmann G.

The health economics of osteoporosis and hormone replacement therapy
pp. 33-33(1)
Author: Prince R.

Osteoporosis: an overview
pp. 33-33(1)
Author: Lindsay R.

Identifying the high-risk post-menopausal woman
pp. 34-34(1)
Author: barrett-Connor E.

The clinical promise of the selective estrogen receptor modulator, raloxifene HCI and the postmenopausal woman
pp. 34-34(1)
Author: Anderson P.W.

Bleeding patterns and endometrial histology with sequential HRT
pp. 34-34(1)
Author: Sturdee D.W.

Why postmenopausal women with an atrophic endometrium bleed
pp. 34-34(1)
Author: Smith S.K.

Can we predict bleeding patterns?
pp. 35-35(1)
Author: Ulrich L.

Endometrial response to continuous-combined HRT
pp. 35-35(1)
Author: Wells M.

Side effects in women using Kliogest (Kliofem) in the UK multicentre study
pp. 35-35(1)
Author: Barlow D.

A general practitioner's outlook on long term HRT and the GP/specialist relationship
pp. 35-35(1)
Author: Drew S.

Estrogen and memory in women
pp. 36-36(1)
Author: Sherwin B.B.

P06.022 - A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease in the Baltimore longitudinal study of aging
pp. 36-36(1)
Authors: Morrison A.; Kawas C.; Resnick S.; Corrada M.; Zonderman A.; Brookmeyer R.

Estrogen replacement in women treated for depression and dementia
pp. 36-36(1)
Author: Schneider L.

The cause of premature menopause
pp. 36-37(2)
Author: Godfree V.A.

Premature menopause: consequences to the women
pp. 37-37(1)
Author: Davis S.R.

The management of bone loss in young women with estrogen deficiency.
pp. 37-37(1)
Author: Delmas P.D.

Younger women: Is there ever a need for HRT? Dealing with the complications of therapy
pp. 37-37(1)
Author: Doren M.

Metabolic determinants of atherosclerosis
pp. 38-38(1)
Author: Krauss R.M.

Hormone replacement therapy and carbohydrate metabolism
pp. 38-38(1)
Author: Gaspard U.J.

Hormone replacement therapy and lipid metabolism
pp. 39-39(1)
Author: Crook D.

Hormone replacement therapy and haemostatic factors
pp. 39-39(1)
Author: Winkler U.H.

Role of estrogens in falls and fractures
pp. 39-39(1)
Author: Birge S.B.

Apnea in postmenopausal women
pp. 40-40(1)
Author: Naftolin F.

Targeted drug delivery in gynecology: vaginal progesterone (P) and the first uterine pass effect
pp. 40-40(1)
Authors: Bulletti C.; de Ziegler D.; Flamigni C.; Giacomucci E.; Polli V.; Bolelli G.; Franceschetti F.

Hormone replacement therapy women over 60 management of osteoporosis prevention
pp. 40-41(2)
Author: Palacios S.

Hormones and heart disease and women
pp. 41-41(1)
Author: Barrett-Connor E.

Hormone replacement therapy in women over 60. Management of cancer risks
pp. 41-41(1)
Authors: Foidart J.M.; Desreux J.; Beliard A.; Delvigne A.C.; Colin C.; Fournier S.; de Lignieres B.

HRT in women over 60 management of compliance
pp. 42-42(1)
Author: de Lignieres B.

Canadian and American differences in the experience of menopause
pp. 43-43(1)
Author: Cobb J.O.

Attitude of physicians towards HRT. Analysis of a pre-test.
pp. 43-43(1)
Authors: Rozenberg S.; Kroll M.; Lefever A.; Riera C.; Vandromme J.; Paesmans M.; Ham H.

Menopause and low-income women of ethnic minorities: the significance of social class and cultural difference
pp. 43-43(1)
Author: Weiss B.

The relative contribution of change in paid work status to change in health outcomes in midlife
pp. 44-44(1)
Authors: Dennerstein L.; Dudley E.C.; Hopper J.L.

Perceived health among middle-aged women: networking between individual, environment and society
pp. 44-44(1)
Authors: Peltonen R.S.; Krantz I.

A study of the effect of kliogest and livial on quality of life in post-menopausal women.
pp. 44-44(1)
Authors: Joyce M.; O'Keeffe N.; Sheppard B.L.; Bonnar J.

A study of the effect of Kliogest and Livial on coagulation and fibrinolysis in post-menopausal women.
pp. 44-44(1)
Authors: Bonnar J.; Norris L.A.; O'Keeffe N.; Joyce M.; Sheppard B.L.

No influence of hormone replacement therapy on the risk of thrombotic and haemorrhagic stroke-results from a nationwide case-control study.
pp. 45-45(1)
Authors: Pedersen A.T.; Lidegaard .; Kreiner S.; Ottesen B.

The effect of estrogen replacement therapy on plasma coagulation and fibrinolysis in women with non insulin dependent diabetes mellitus
pp. 45-45(1)
Authors: Hahn L.; Mattsson L.-A.; Andersson B.; Tengborn L.

Tibolone: effects on cardiovascular risk factors: lipid and haemostasis.
pp. 45-45(1)
Authors: Bjarnason N.; Bjarnason K.; Haarbo J.; Kicovic P.; Christiansen C.

Changes in coagulation proteins in postmenopausal women treated with Estring(R) (a new type of intravaginal ring releasing continuous estradiol 17 beta) compared to conjugated equine estrogens in a vaginal cream
pp. 46-46(1)
Authors: Hickox P.G.; Johnson T.; Birgerson L.

The influence of different progestin doses on coagulation parameters in women receiving hormone replacement therapy
pp. 46-46(1)
Authors: Straube W.; Romer T.; Foth D.; Frick U.

Transdermal continuous oestrogen and interrupted progestogen as a novel 'bleed-free' regime of HRT for postmenopausal women
pp. 46-46(1)
Authors: Cameron S.T.; Glasier A.F.; Baird D.T.

A new regimen of continuous combined oral hormone replacement therapy with oscillating doses of estrogen
pp. 46-46(1)
Author: Koninckx P.R.

Pilot study of continuous combined post-menopausal HRT using alternate day or twice weekly vaginal progesterone
pp. 47-47(1)
Authors: Wardle P.; Joels L.; Hinks J.; Watt M.

Sequential three-monthly versus monthly HRT: a prospective double-blind randomised study
pp. 47-47(1)
Authors: van der Mooren M.J.; Hanselaar A.G.J.M.; Schiff C.P.T.; Girardin-v.d. Klaauw C.C.A.M.; Rolland R.

Adverse endometrial effects during long cycle hormone replacement therapy
pp. 48-48(1)
Authors: Scandinavian Long Cycle Study Group; Cerin A.; Bjarnason K.; Heldaas K.; Thomsen H.K.; Moeller B.

International long-term randomised controlled trial of hormone replacement therapy - UK feasibility study
pp. 48-48(1)
Authors: Vickers M.R.; Meade T.W.; Wilkes H.C.

A longitudinal, comparative study of the effect of kliogest and livial on plasma lipids in post-menopausal women.
pp. 48-48(1)
Authors: Sheppard B.L.; O'Keeffe N.; Joyce M.; Norris L.A.; Bonnar J.

The effect of tibolone on serum lipid and lipoprotein levels
pp. 49-49(1)
Authors: Ertungealp E.; Erel C.T.; Seyisoglu H.; Senturk L.; Gezer A.; Colgar U.

Plasma lipids in combined continuous HRT - IUD levonorgestrel vs oral provera
pp. 49-49(1)
Authors: Stuckey B.; Gutteridge D.; Evans D.; Coulden S.; Bozich T.; Robertson K.; Retallack R.; Phillips J.; Knowles S.; Dhaliwal S.; Jamrozik K.; Keogh E.

Mechanisms regulating low density lipoprotein levels in postmenopausal women
pp. 49-49(1)
Authors: Karjalainen A.H.; Heikkinen J.E.; Savolainen M.J.; Backstrom A.-C.; Salinto M.; Kesaniemi Y.A.

Long-term effects of dydrogesterone and medroxyprogesterone on lipoprotein indicators of cardiovascular risk in postmenopausal women
pp. 49-49(1)
Authors: Gelfand M.M.; Fugere P.; Bissonnette F.; Wiita B.; Mol M.

The effects of exogenous testosterone on lipid metabolism & insulin resistance in postmenopausal women.
pp. 50-50(1)
Authors: Sands R.; Studd J.; Seed M.; Doherty E.; Kelman D.; Andrews G.; Jones J.; Panay N.; Khastiger G.; Carter G.; Alaghband-Zadeh J.

The prevalence of osteopenia and osteoporosis according to who criteria, in women in their seventh decade and the sensitivity and specificity of bone densitometry referral criteria.
pp. 50-50(1)
Authors: Ballard P.A.; Steel S.A.; Langton C.M.; Purdie D.W.

The relative contributions of aging and menopause in determining involutional osteopenia
pp. 50-50(1)
Authors: Gambacciani M.; Piaggesi L.; De Simone L.; Cappagli B.; Ciaponi M.; Genazzani A.

Prospective comparison of biochemical and radiological markers of bone mineral status in early postmenopausal women
pp. 51-51(1)
Authors: O'Herlihy C.; O'Rorke A.; Barrett E.; Donnelly V.; Tunney P.; Fottrell P.F.

Bone density, blood viscosity and body mass index in the postmenopausal women
pp. 51-51(1)
Authors: Kaibara M.; Aisaka K.; Ryou Y.; Morioka H.; Watanabe T.; Minaguchi T.; Nisihira N.

Relationship of serum vitamin K1 and K2 levels to bone mineral density in climacteric women
pp. 51-51(1)
Authors: Takagi T.; Masuhiro K.; Nakamura M.; Kanai T.

Physical activity: preventive of osteoporosis?
pp. 51-51(1)
Authors: David A.; Tachner G.; Dvir Z.; David Y.; Amit-David A.

Development of a photographic digital imaging technique for measuring skin irritation with transdermal patches
pp. 52-52(1)
Authors: Ross D.; Pike B.; Godfree V.; Cooper A.; Spencer C.; Whitehead M.

Cross-over comparison of skin irritation with two transdermal oestradiol patches in women with a history of patch site skin irritation
pp. 52-52(1)
Authors: Ross D.; Godfree V.; Cooper A.; Rees C.; Hart D.; Kingsland C.; Rees E.; Whitehead M.

Bone density and skin thickness changes in patients on long tern steroid therapy treated with long term hormone replacement therapy.
pp. 52-52(1)
Authors: Baron Y.M.; Brincat M.P.; Galea R.

A screening model for osteoporosis using dermal skin thickness and bone densitometry.
pp. 53-53(1)
Authors: Brincat M.P.; Galea R.; Baron Y.M.

Skin thickness measurement for early detection of osteoporosis in menopausal women with transdermal ultrasound
pp. 53-53(1)
Authors: Baziad A.; Salim A.; Hestiantoro A.; Kuhl H.

Effect of topical ammonium lactate on epidermal atrophy in postmenopausal women.
pp. 53-53(1)
Authors: Faure M.; Drapier-Faure E.

Effect of 17-oestradiol on endothelin-1 release by human umbilical vein endothelial cells
pp. 53-53(1)
Authors: Wingrove C.S.; Stevenson J.C.

Modulation of VEGF expression in cultured human blood vessels: effect of 17-oestradiol.
pp. 54-54(1)
Authors: Akkad A.A.; Habiba M.A.; Bell S.C.; Al-Azzawi F.

Levormeloxifene, a non-steroidal estrogen receptor therapeutic, reduces serum cholesterol and prevents aortic cholesterol accumulation in cholesterol fed rabbits.
pp. 54-54(1)
Authors: Holm P.; Shalmi M.; Korsgaard N.; Guldhammer B.; Skouby S.O.; Stender S.

The influence of acute and chronic exposure to 17--estradiol on the arterial contractility in rat thoracic aorta.
pp. 54-54(1)
Authors: Andersen H.L.; Weis J.U.; Korsgaard N.; Shalmi M.

Relaxant effects of progesterone and synthetic progestins in rat aorta in comparison to 17-estradiol
pp. 55-55(1)
Authors: Glusa E.; Wagner S.; Graser T.; Oettel M.

Raloxifene inhibits aortic accumulation of cholesterol in ovariectomized, cholesterol-fed rabbits.
pp. 55-55(1)
Authors: Bjarnason N.; Haarbo J.; Byrjalsen I.; Kauffman R.; Christiansen C.

Urogenital atrophy: need for standardized assessment of outcomes-a rut committee report
pp. 56-56(1)
Authors: Bachmann G.; Cardozo L.; McClish D.; Fonda D.

Safety study on the action of the vaginal ring estring(R) on endometrium after a long-term treatment in postmenopausal women.
pp. 56-56(1)
Author: Pigne A.

A meta-analysis of the effect of estrogen on urogenital atrophy.
pp. 56-56(1)
Authors: Cardozo L.; Bachmann G.; Fonda D.; McClish D.

Targeted drug delivery in gynecology: vaginal progesterone (P) and the first uterine pass effect.
pp. 57-57(1)
Authors: Bulletti C.; de Ziegler D.; Flamigni C.; Giacomucci E.; Polli V.; Bolelli G.; Franceschetti F.

Vaginal progesterone (P) in menopause: long term acceptability of a new therapeutic option for physiological progesterone replacement.
pp. 57-57(1)
Authors: Jaaskelainen A.; Shaerer E.; de Ziegler D.

The effect of HRT on anorectal function in postmenopausal women with faecal incontinence a preliminary study
pp. 58-58(1)
Authors: Donnelly V.; O'Connell P.; O'Herlihy C.

The effect of hormone replacement therapy on peripheral blood flow in postmenopausal women
pp. 58-58(1)
Authors: Haines C.; Lau T.; Chung T.; Yim S.; Sanderson J.

Effects of hormone replacement therapy on duplexsonographic quantification of carotid atherosclerosis in postmenopausal women
pp. 58-58(1)
Authors: Romer T.; Griewing B.; Gunther A.

The effects of continuous combined oral oestradiol and norethisterone on pulsatility index in internal carotid artery in women taking cyclical opposed H.R.T.
pp. 58-58(1)
Authors: McCullough W.; Gangar K.; Chilcott I.; Penny J.; Gangar E.; Morris J.

The effects of continuous combined oral oestradiol and norethisterone on pulsatility index in internal carotid artery in previously untreated women
pp. 59-59(1)
Authors: Gangar K.F.; McCullough W.; Penny J.; Morris J.; Gangar E.; Scrase E.

The effects of progestagens, as part of combined hormone replacement, on vascular tone
pp. 59-59(1)
Authors: Luckas M.; Gleeve T.; Biljan M.; Kingsland C.

The influence of autonomic imbalance on the symptoms due to blood flow disorder
pp. 59-59(1)
Authors: Aso K.; Miyasaka N.; Aso T.

Smoking reduces the beneficial effects of continuously combined hormone replacement therapy in reducing bone turnover
pp. 60-60(1)
Authors: de Valk-de Roo G.W.; Netelenbos J.C.; Peters-Muller E.R.A.; van de Weijer P.H.M.; Kenemans P.

Impact of smoking on bone mineral density of menopausal patients
pp. 60-60(1)
Authors: Celikkanat H.; Moroy P.; Gulerman C.; Doganay M.; Alaybeyoglu L.; Sener B.; Gokmen O.

Characteristics of menopause among Chinese women
pp. 60-60(1)
Author: Ge Q.-s.

Prevalence of osteoporosis in women attending menopause clinic, Chulalongkorn hospital
pp. 61-61(1)
Authors: Limpaphavom K.; Angkawanich P.; Panyakhamlerd K.; Taechakraichana N.

Risk factors of osteoporosis in Thai women attending menopause clinic at Chulalongkorn hospital
pp. 61-61(1)
Authors: Limpaphayom K.; Bunyavejchevin S.; Angkawanich P.; Panyakhamlerd K.; Poshyachinda M.; Taechakraichana N.

Age and race relationship of women presenting with Colle's or trocranteric fractures
pp. 61-61(1)
Authors: Premitha D.; Raman S.; Rozman I.

Premature menopause: the experience from the woman's perspective
pp. 61-61(1)
Author: Boughton M.A.

The impact of androgen levels on bone density in patients with premature ovarian failure
pp. 62-62(1)
Authors: Albrecht A.E.; Hartmann B.W.; Laml T.; Nakle B.; Huber J.C.

Genetics of the age at menopause in a large Australian twin study
pp. 62-62(1)
Authors: Christiansen B.J.; Martin N.G.

Do ovarian stimulation treatments modify the age of menopause and of appearance of climateric symptoms
pp. 62-62(1)
Authors: Demoulin A.; Dubois M.; Gillain D.; Lambotte R.

Management of the woman with premature menopause
pp. 62-63(2)
Authors: Norman R.J.; Clark A.; Phillipson G.; Davies T.

Early menopause - problems faced by women with early loss of ovarian function
pp. 63-63(1)
Authors: McCall Y.; Earle C.; Bozich T.; Stuckey B.

Women's opinion about the re-occurrence of vaginal bleeds before their start with a sequential HRT regimen for the prevention of osteoporosis
pp. 63-63(1)
Authors: van de Weijer P.; Barentsen R.; Kenemans P.

Histopathology and bleeding patterns of continuous combined HRT administered transdermally and orally
pp. 63-63(1)
Authors: Mattson L.; Iding R.; van Kempen P.; Crepin G.; Bolis P.; Bacchi-Modena A.; Bohnet H.

Randomised double-blind dose-ranging study of the endometrial effects of oral trimegestone with 17 oestradiol in postmenopausal women
pp. 64-64(1)
Authors: Ross D.; Godfree V.; Pryse-Davies J.; Cooper A.; Morris K.; Spencer C.; Whitehead M.

Bleeding-related drop-out incidence is significantly lower during treatment with livial than with Kliogest
pp. 64-64(1)
Authors: Christau S.; Hammar M.; Nathorst-Boos J.; Rud T.; Johannes E.

The occurrence of different endometrial histological findings in perimenopausal symptomatic women
pp. 64-64(1)
Authors: Carones M.B.; Simionato S.; Clerici P.; Sbano E.; Frigerio A.; Miragoli A.; Vignali M.

Ultrasound morphometric assessment of the endometrium in symptomatic postmenopausal women
pp. 65-65(1)
Authors: Miragoli A.; Carones M.B.; Simionato S.; Vignali M.

Comparing the effect of combined oestrogen and progesterone therapy with the effect of simvastatin therapy on lipid levels in postmenopausal women with hypercholesterolaemia
pp. 65-65(1)
Authors: Darling G.M.; Johns J.A.; Davis S.R.

Transdermal oestradiol lowers cholesterol in moderately hypercholesterolemic women
pp. 65-66(2)
Authors: Samsioe G.; &unknown;9aberg A.; Balsell G.; Sandin K.; Huls G.

Influence of type and dose of oestrogen on plasma lipids in post-menopausal women
pp. 66-66(1)
Authors: Harvey P.J.; Wing L.M.H.; Tallis G.

17-oestradiol continuous combined with dydrogesterone reduces Lp(a) in postmenopausal women
pp. 66-66(1)
Authors: Mijatovic V.; van der Mooren M.J.; van de Weijer P.H.M.; Voetberg G.A.; Peters-Muller E.R.A.; Netelenbos J.C.; Kenemans P.

The effect of the menopause on plasma concentrations of lipoprotein(a)
pp. 66-66(1)
Authors: Cheung L.; Chung T.; Lam C.; Haines C.

Long-term comparison three: hormone replacement therapies on serum lipids and lipoprotein(a)
pp. 67-67(1)
Authors: Hanggi W.; Lippuner K.; Riesen W.; Jager P.; Birkhauser M.H.

Endometrial assessment of women on continuous combined HRT
pp. 68-68(1)
Authors: Calder A.L.; Piegsa K.; Davis J.A.; Bryden F.M.; Hart D.M.; Wells M.J.

Comparison of transvaginal ultrasonography and endometrial biopsy in postmenopausal women on different HRT regimens
pp. 68-68(1)
Authors: Hanqqi W.; Bersinger N.; Altermatt H.; Birkhauser M.

Transvaginal sonography and endometrial histopathology in postmenopausal women treated with hormonal replacement therapy
pp. 68-68(1)
Authors: Lindgren R.; Mattsson L.-A.; Lagrelius A.; Sandin K.; Karlsson K.; Risberg B.

The leicester endometrial needle sampler (LENS) in the postmenopausal patient : a novel outpatient hysteroscopy-directed biopsy
pp. 68-68(1)
Authors: Habiba M.A.; Bell S.C.; Al-Azzawi F.

Morphometric and immunohistological evaluation of the endometrium of menopausal women treated by oestrogen and crinone, a new slow-release vaginal progesterone
pp. 69-69(1)
Authors: Casanas-Roux F.; Nisolle M.; Smets M.; Donnez J.

Endometrial histology, in long-cycle HRT, for three years
pp. 69-69(1)
Authors: Englund D.E.; Damm S.; Hemmingsson E.; Linden M.; Ljunblad U.; Nilsen T.; Risberg B.; Schnittger A.

Bone density after combined continuous HRT - advantage of L-norgestrel at the HIP site?
pp. 69-69(1)
Authors: Gutteridge D.; Stuckey B.; Evans D.; Coulden S.; Bozich T.; Retallack R.; Dhaliwal S.; Bhagat C.; Jamrozik K.; Keogh E.

The effect of six years nonbleeding HRT (Tibolone) on the female skeleton
pp. 69-69(1)
Authors: Rymer J.; Chapman M.G.; Robinson J.; Fogelman I.

Hormone replacement therapy improves postural balance function in menopausal women
pp. 70-70(1)
Authors: Naessen T.; Lindmark B.; Lagerstrom C.; Larsen H.-C.; Persson I.

The effects of surgical menopause and parenteral hormone replacement therapy on bone density, menopausal symptoms and hormone profiles
pp. 70-70(1)
Authors: Anderson C.; Raju K.; Forsling M.; Wheeler M.

Bone loss in women over 60 years prevented by ultra-low doses of 17- estradiol
pp. 70-70(1)
Authors: Naessen T.; Berglund L.; Ulmsten U.

Baseline characteristics do not affect the response to raloxifene hydrochloride in japanese women with osteoporosis
pp. 70-71(2)
Authors: Morii H.; Orimo H.; Taketani Y.; Ishii J.; Inoue T.; Fujita T.; Ohashi Y.; Huster W.; Mitlak B.

Enhanced nitric oxide formation by 17-estradiol in vascular smooth muscle may explain its ability to attenuate vasoconstriction
pp. 71-71(1)
Authors: Binko J.; Majewski H.

I.V. administration of conjugated estrogen improves endothelium dependent flow mediated vasodilatation in postmenopausal women
pp. 71-71(1)
Authors: Schenck-Gustafsson K.; Al-Khalili F.; Eriksson M.; Landgren B.-M.

Effects of acute and short-term estradiol administration on serum nitric oxide levels in postmenopausal women
pp. 71-72(2)
Authors: Cicinelli E.; Ignarro L.J.; Balzano G.; Romano F.; Ruccia C.; Cataldi E.; Schonauer L.M.

Improved nitric oxide synthesis in postmenopausal women treated with 17-estradiol valerate - evidence for responders and non-responders
pp. 72-72(1)
Authors: Imthurn B.; Rosselli M.; Jager A.W.; Dubey R.K.; Keller P.J.

The vasorelaxant effect of a series of estrogenic agonists and partial agonists is not correlated to their affinity at the estrogen receptor
pp. 72-72(1)
Authors: Sheardown M.J.; Thorpe S.M.

Low-dose HRT reduces vascular resistance in the central retinal artery
pp. 72-72(1)
Authors: van Baal W.M.; Mijatovic V.; Stehouwer C.D.A.; van Vugt J.M.G.; Dekker G.A.; van Geijn H.P.; Peters-Muller E.R.A.; Voetberg G.A.; van der Mooren M.J.; Kenemans P.

Effect of hormone replacement on insulin sensitivity in women after oophorectomy
pp. 73-73(1)
Authors: Roberts R.N.; Lumsden M.A.; Petrie J.; Monaghan S.; Connell J.M.C.

Effects of oral or transdermal oestradiol combined with cyclical oral norethisterone acetate on insulin and glucose metabolism in postmenopausal women
pp. 73-73(1)
Authors: Spencer C.; Godsland I.F.; Cooper A.; Ross D.; Whitehead M.; Stevenson J.

Metabolic effects of 12-month percutaneous DHEA replacement therapy in postmenopausal women
pp. 73-73(1)
Authors: Diamond P.; Cusan L.; Gomez J.L.; Belanger A.; Labrie F.

The influence of postmenopausal hormone replacement therapy on body composition
pp. 73-73(1)
Authors: Hanggi W.; Lippuner K.; Horber F.; Birkhauser M.; Jager P.

Controlled study of metabolic effects of estrogen-progestogen and tibolone over 2 years on postmenopausal women
pp. 74-74(1)
Authors: Milner M.; Kelly A.; Harrison R.

Route of oestrogen replacement confers distinct and divergent effects on substrate metabolism and body composition in postmenopausal women
pp. 74-74(1)
Authors: O'Sullivan A.J.; Crampton L.; Freund J.; Ho K.K.Y.

Oestradiol implants, patches and reported symptoms
pp. 74-74(1)
Author: Alder E.M.

Chlormadinone acetate(CA) to micronized progesterone(MP) in the sequential hormonal replacement therapy(HRT) of the menopause
pp. 74-74(1)
Authors: Pelissier C.; Maroni M.; Yaneva H.; Brin S.; Jonder M.

Compared single dose pharmacokinetics of S21102, a new estradiol transdermal patch with two marketed drug products
pp. 75-75(1)
Authors: Rocher I.; Lhote O.; Brion N.; Deloffre P.; Jochemsen R.; Tsouderos Y.

A new transdermal noretihisterone acetate: efficacy and potentiality of a once week form
pp. 75-75(1)
Authors: Raynaud J.-P.; Levrier M.; Calaf J.; Jondet M.; Fiet J.; Auzerie J.; Sarrazin B.; Pelissier C.

Long-term follow up of postmenopausal patients treated with estradiol patches-eight year experience
pp. 75-76(2)
Author: Aksu M.F.

Long-term clinical performance of two different HRT regimens: oral combined estrogen progestin and transdermal estrogen with sequential progestin
pp. 76-76(1)
Authors: Luotola H.; Pyorala T.; Bjorn M.; Kaariainen J.; Puolakka J.

Postmenopausal women without vasomotor symptoms have better stress-coping than women with symptoms
pp. 76-77(2)
Authors: Nedstrand E.E.; Wijma K.; Lindgren M.B.; Hammar M.L.

Is Hormone replacement therapy a risk factor for low back pain among postmenopausal women?
pp. 77-77(1)
Authors: Brynhildsen J.O.; Hammar M.L.

Health status and climacteric complaints in perimenopausal women in Hong Kong
pp. 77-77(1)
Authors: Chan S.G.; Ho S.C.; Yip Y.B.; Cheng Y.K.

Applied relaxation - a behavioural treatment for vasomotor symptoms among postmenopausal women
pp. 77-77(1)
Authors: Nedstrand E.E.; Melin A.I.; Wijma K.; Hammar M.L.; Lindgren M.B.

Randomised, double blind, placebo controlled, cross over study on the effect of 2 mg oestradiol on acute menopausal symptoms in Chinese women
pp. 78-78(1)
Authors: Chung T.; Yip S.; Lam P.; Haines C.

CGRP-A neuropeptide responsible for vasomotor symptoms around menopause?
pp. 78-78(1)
Authors: Wyvon Y.M.; Frisk J.; Lindgren R.; Lundeberg T.; Hammar M.L.

Effects of estrogens, tamoxifen, progestins, androgens and dietary soy on the mammary gland and endometrium of macaques
pp. 78-78(1)
Authors: Cline J.; Soderqvist G.; Foth D.; Romer T.; von Schoutz B.

Important androgenic component in the stimulatory effect of dehydroepiandrosterone (DHEA) on bone density in the rat
pp. 79-79(1)
Authors: Martel C.; Labrie F.

Influence of hormone replacement therapy on gonadotropin pulsatility in postmenopausal women
pp. 79-79(1)
Authors: Vujovic S.; Drezgic M.; Stojanovic M.; Beleslin B.; Tazev S.; Trbojevic B.

The influence of MPA treatment in HRT on vascular smooth muscle cells
pp. 79-79(1)
Authors: Okubo T.; Urabe M.; Tsuchiya H.; Iwasa K.; Yokota K.; Kikuchi N.; Honjo H.

Occurrence and modification of intimal hyperplasia by the changes in female hormones
pp. 80-80(1)
Authors: Azuma H.; Sato J.; Hamasaki H.; Masuda H.; Tamaoki S.; Obayashi S.; Aso T.

Inhibitory effect of a new non-steroidal pure antiestrogen (EM-800) in combination with DHEA on human ZR-75-1 breast tumors in nude mice
pp. 80-80(1)
Authors: Couillard S.; Labrie C.; Gauthier S.; Labrie F.

Post-menopausal hormone replacement therapy is associated with improved arterial physiology
pp. 80-80(1)
Authors: McCrohon J.; McCredie R.; Pike A.; Abbey M.; Celermajer D.

The effect of low-dose estrogen treatment on brain blood flow
pp. 80-80(1)
Authors: Ohkura T.; Iwasaki N.; Yaoi Y.

Comparison of uterine and carotic artery pulsatility index during oral or transdermal HRT
pp. 81-81(1)
Authors: Cacciatore B.; Paakkari I.; Toivonen J.; Ylikorkala O.; Tikkanen M.J.

Effects of oral norgestrel and vaginal progesterone on uterine artery pulsatility index in oestrogen-treated postmenopausal women
pp. 81-81(1)
Authors: Ross D.; Jurkovic D.; Spencer C.; Colville N.; Collins W.; Whitehead M.

Study of the effect of hormone replacement therapy on cardiovascular haemodynamics
pp. 81-81(1)
Authors: Hayward C.S.; Wren B.G.; Knight D.C.; Kelly R.P.

Medroxyprogesterone acetate (MPA) but not natural progesterone (P) reverses the effect of estradiol 17 (E2) upon exercise induced myocardial ischemia. A double-blind cross-over study
pp. 82-82(1)
Authors: Rosano G.M.C.; Sarrel P.M.; Chierchia S.L.; Morgagni G.L.; Donato P.; Ermini M.; Leonardo F.; Sontag G.; Beale C.; Collins P.

Mood and menopause: update 1992-1996
pp. 82-82(1)
Author: Holte A.

Psychological and social concomitants of the female menopause: a longitudinal study
pp. 82-82(1)
Author: Perz J.M.

Cognitive behaviour therapy for depressed mood in menopausal women
pp. 83-83(1)
Author: Greene J.G.

Correlation of sex-hormones to sex-role identification and vasomotor complaints during the menopausal transition in healthy Norwegian women
pp. 83-83(1)
Authors: Overlie I.; Morkrid L.; Finset A.; Holte A.

Body image, hormone replacement therapy, and sexual function, among postmenopausal women
pp. 83-83(1)
Authors: Deeks A.A.; McCabe M.P.

The effects of short-term ERT on cognitive performance in naturally postmenopausal women
pp. 84-84(1)
Authors: Woodruff W.J.; Thomas S.L.; Karlan B.A.; Rapkin A.J.

Bone mineral density (BMD) at lumbar spine and femoral neck in hysterectomised women treated with chronic oestradiol implantation
pp. 84-84(1)
Authors: Purdie D.W.; Ballard P.A.; Wahab M.; Cooper A.

3 years prevention of postmenopausal bone loss: conjugated estrogen-medroxyprogesterone vs tibolone
pp. 84-84(1)
Authors: Thiebaud D.; Bigler J.; Pache T.; Welti H.J.; Burckhardt P.

Influence of vitamin D receptor polymorphism on postmenopausal bone density and response to HRT
pp. 85-85(1)
Authors: Jagger C.; Farish E.; Spooner R.; Hart D.M.

Effectiveness of tibolone X placebo in postmenopausal women
pp. 85-85(1)
Authors: Wender M.C.O.; Freitas F.M.; Castro J.A.S.; Mattiello S.S.; Estery C.; Finkelstejn A.

The administration of Tibolone: reduces the untoward effects of GnRH-a: preliminary results
pp. 85-85(1)
Authors: Bontis J.; Pados G.

Prevention of postmenopausal bone loss using tibolone or conventional peroral or transdermal hormone replacement therapy (HRT) with 17- oestradiol (E2) and dydrogesterone.
pp. 86-86(1)
Authors: Lippuner K.; Hanggi W.; Birkhauser M.; Jaeger P.

Influence of treatment satisfaction and quality of life on the overall effectiveness of two topical oestrogen treatments for atrophic vaginitis
pp. 86-86(1)
Authors: Burnet R.; Craven R.; Radden H.; Weisberg E.; Bjork; Ryan S.; Hopkins H.

The vaginal echo system in menopause and influence of hormonal replacement therapy
pp. 86-87(2)
Authors: Platz-Christensen J.; Holst E.; Granberg S.; Larsson P.

A randomized study to compare the efficacy of a vaginal ring (estradiol) with a vaginal pessary (estriol) in postmenopausal women (PMW) with urinary symptoms (US).
pp. 87-87(1)
Authors: Lose G.; Englev E.

Vagifem vs Premarin(R) vaginal cream - a comparative evaluation
pp. 87-87(1)
Authors: Devlin C.; Gelfan M.M.; Nanavati N.; Powell M.; Steinberg W.M.; Wu F.; Rioux J.E.

The use of two estrogen preparations (a combined contraceptive pill v.s. conjugated estrogen cream) intravaginally to treat urogenital symptoms in Thai post-menopausal women: a comparative study.
pp. 87-88(2)
Authors: Chompootaweep S.; Nunthapisud P.; Trivijitsilp P.; Sen trakul P.; Dusitsin N.

The effect of the dydrogesterone dose in continuously combined HRT regimes on micturition complaints
pp. 88-88(1)
Authors: Kok A.; Burger C.; van de Weijer P.; Voetberg G.; Peters-Muller E.; Kenemans P.

Sustained-release estradiol implants in HRT: one-year results on hormone levels and menopausal symptoms
pp. 88-88(1)
Authors: Suhonen S.P.; Lahteenmaki P.; Rauramo I.

Megestrol acetate to treat vasomotor symptoms
pp. 88-88(1)
Authors: Rees M.; Brockie J.; Suffling K.; O'Byrne K.; Harris A.; Clarke P.

Control of menopausal symptoms in women denied oestrogen using unopposed megestrol acetate
pp. 89-89(1)
Authors: Ekevall K.; Barnes J.; Hart D.M.

Use of micronised progesterone in women under estrogen replacement therapy: oral vs vaginal route
pp. 89-89(1)
Authors: Figueroa-Casas P.R.; Delgado E.; Vieder C.; Rodriguez-Vidal D.

Cardiovascular risk factors, bleeding patterns and endometrial histology in postmenopausal women taking sequential combined estradiol and dydrogesterone (Femoston), results from a one-year study
pp. 89-89(1)
Authors: Gelfand M.M.; Ferenczy A.

Clinical grouping of hormone replacement therapy
pp. 90-90(1)
Authors: Hutton J.; Kletchko S.; Toop L.; Moore D.; Scanlon L.; Bennett W.

Pharmacokinetics of a new estradiol matrix patch in healthy postmenopausal volunteers and symptomatic women
pp. 90-90(1)
Authors: Muller P.; Botta L.; Lefevre G.; Ezzer F.

Tolerability and adhesion characteristics of a new matrix patch (Estraderm MX 50)
pp. 90-90(1)
Authors: Della Cioppa G.; Berger R.; Colton J.; Dillard C.

Efficacy and tolerability of a new oestradiol matrix patch (Estraderm MX(R) 50) in the treatment of moderate-to-severe hot flushes
pp. 91-91(1)
Authors: The Estraderm MX Study Group; Crosignani P.; de Aloysio D.; Pisati R.; Huls G.

Efficacy and tolerability benefits of new matrix patches (Estraderm MX(R) 50 and 100) in the treatment of moderate-to-severe postmenopausal symptoms
pp. 91-91(1)
Authors: The Estraderm MX Study Group; Snijders M.; Troostwijk A.; The H.; van Buuren A.; Monza G.

Efficacy and tolerability of a new low dose matrix patch (Estraderm MX(R) 25) in the treatment of mild-to-moderate menopausal symptoms
pp. 91-91(1)
Authors: Chevallier O.; Keil D.; Huls G.; Monza G.

Lack of microbial proliferation and phototoxic potential of a new oestradiol matrix patch (Estraderm MX(R))
pp. 91-91(1)
Authors: Huls G.; Della-Cioppa G.; Berger R.; Harper R.; Oelrich D.

Postural balance, evaluated by dynamic posturography, is increased by hormone replacement therapy among postmenopausal women
pp. 92-92(1)
Authors: Hammar M.L.; Lindgren R.; Berg G.E.; Moller C.G.; Niklasson M.K.

A prospective study of bone loss in perimenopausal Australian-born women
pp. 92-92(1)
Authors: Guthrie J.R.; Ebeling P.R.; Barrett-Connor E.; Hopper J.L.; Dennerstein L.; Wark J.D.

Bone turnover markers and bone density across the menopausal transition
pp. 92-92(1)
Authors: Ebeling P.; Atley L.; Guthrie J.; Burger H.; Dennerstein L.; Hopper J.; Wark J.

Physical activity, climacteric symptoms and bone mass in hong kong perimenopausal women
pp. 93-93(1)
Authors: Ho S.C.; Chan S.G.; Yip V.; Chan C.; Law C.L.

Can the fast bone loss in osteoporotic patients be stopped with vitamin d metabolites as an alternative to estrogens?
pp. 93-93(1)
Authors: Dambacher M.A.; Merlin C.; Neff M.

Diagnosis of osteoporosis by ultrasound densitometrie-comparative data from a pilot study
pp. 93-94(2)
Authors: Beckmann M.; Jap D.; Mohrmann T.; Bodden-Heidrich R.; Niederacher D.; Crombach G.; Langeneckhardt D.; Ratjen C.; Bender H.

Intrauterine progestin therapy in HRT: results of a four-year follow-up study
pp. 94-94(1)
Authors: Suhonen S.P.; Holmstrom T.; Lahteenmaki P.

One year results of continuous intrauterine compared to cyclic oral progestin administration in combined HRT in 200 perimenopausal women
pp. 94-94(1)
Authors: Boon J.; Scholten P.; Heintz A.; Euser R.; Oldenhave A.

Combined oral conjugated equine estrogen and LNG IUS as a hormonal replacement therapy regimen in perimenopausal women
pp. 94-94(1)
Authors: Hampton N.; Rees M.; Barlow D.H.; Lowe D.G.; Guillebaud J.

Prospective study of levonorgestrel intrauterine system (LN IUS) as opposition for oestrogen therapy
pp. 95-95(1)
Authors: Panay N.; Studd J.W.W.; Sands R.; Khastgir G.; Irvine R.; Kelman R.

The use of a levonorgestral-intrauterine device in reduction of withdrawal bleeding in menopausal women with uterine fibroids
pp. 95-95(1)
Authors: Singer A.; Ikomi M.

Evaluation of Crinone(R), a transvaginally administered progesterone containing bioadhesive gel, in women with secondary amenorrhea
pp. 95-96(2)
Authors: Warren M.P.; Shangold M.M.; Biller B.M.K.

Breast cancer and treatment-induced menopause: implications for health education
pp. 96-96(1)
Author: Weiss B.

A randomised controlled trial of hormone replacement therapy in breast cancer patients - a feasibility study
pp. 96-96(1)
Authors: Marsden J.; Sacks N.; Baum M.; Whitehead M.; Crook D.

Doppler flow evaluation of endometrial conditions in postmenopausal breast cancer patients treated with tamoxifen
pp. 97-97(1)
Authors: Fallo L.; Dordoni D.; Palai N.; Ruggeri C.; Daldoss C.; Omodei U.; Boccuti A.M.

Postmenopausal hormone replacement therapy increases mammographic breast tissue density
pp. 97-97(1)
Authors: van der Mooren M.J.; Schijf C.P.T.; Marugg R.C.; Hendriks J.H.C.L.; Ruijs S.H.J.; Rolland R.

Progestin induced apoptosis of normal huma breast cells: an in vivo and in vitro study
pp. 97-97(1)
Authors: Desreux J.; Noel A.; Thomas J.L.; Bernard A.M.; Paris J.; Delansorne R.; Van Cauwenberge J.R.; Van Cauwenberge H.; Francart D.; Heinen V.; Foidart J.M.

The influence of menstrual cycle phase on proliferation of breast epithelial cells in vivo
pp. 97-97(1)
Authors: Soderqvist G.; Isaksson E.; Carlstrom K.; von Schoultz B.; Tani E.; Skoog L.

Changes in systemic hemodynamic parameters during handgrip: relation to the menstrual cycle, to the postmenopause and to the ERT
pp. 98-98(1)
Authors: Cicinelli E.; Ciccone M.; Campagna M.; Balzano G.; Lombardi M.; Falco A.; Federici A.; Schonauer S.; Rizzon P.

Comparison of the effects of transdermal and oral HRT on ambulatory blood pressure in postmenopausal women
pp. 98-98(1)
Authors: Paakkari I.; Hasselblatt R.; Nieminen M.; Cacciatore B.; Toivonen J.; Tikkanen M.; Ylikorkala O.

Randomised double blind placebo controlled crossover study of the effects of hormonin(R) on cardiac risk factors in hypertensive postmenopausal women
pp. 98-99(2)
Authors: Sands R.; Crook D.; Studd J.; Warren J.; Foster C.; Worthington M.; Cruickshank J.; Sooranna S.; Panay N.; Coats A.

The influence of long-term HRT treatment on ambulatory bloodpressure in older women with coronary artery disease
pp. 99-99(1)
Authors: Pripp U.M.; Hall G.; Landgren B.-M.; Schenck-Gustafsson K.

The influence of postmenopausal oestradiol-dydrogesterone therapy on blood pressure
pp. 99-99(1)
Author: van der Mooren M.

Menopause, HRT and blood pressure: a cross-sectional analysis of 3,036 women
pp. 100-100(1)
Authors: Gambacciani M.; Affinito P.; Altieri P.; Bertoli P.; Galbiati G.; Lo Dico G.

Hormone replacement theraphy after transcervical resection of the endometrium
pp. 100-100(1)
Authors: Istre O.; Holm-Nielsen P.; Bourne T.; Forman A.

Treatment of recurrent bleeding disorders during hormone replacement therapy by transcervical endometrial ablation
pp. 100-100(1)
Author: Romer T.

A survey of hormone replacement therapy awareness and usage following hysterectomy
pp. 101-101(1)
Authors: Panay N.; Rowe R.; Studd L.E.

Hysterectomy, hormone therapy and self perception of menopausal status
pp. 101-101(1)
Authors: Taffe J.R.; Garamszegi C.V.; Dudley E.C.; Dennerstein L.

The risk of myocardial infarction after oophorectomy and hysterectomy
pp. 101-101(1)
Authors: Falkeborn M.; Naessen T.; Persson I.

Prospective study of bone density following premenopausal hysterectomy
pp. 102-102(1)
Authors: Dean S.; Farquharson R.G.; Fraser W.D.

Effects of tibolone compared with a cyclical oestrogen/progestogen regimen on lipoproteins
pp. 102-102(1)
Authors: Farish E.; Barnes J.F.; Fletcher C.D.; Ekevall K.; Hart D.M.

The influence of hormone replacement with conjugated equine estrogen or with estradiol on lipid metabolism in postmenopausal women
pp. 102-102(1)
Authors: Nakagawa T.; Murakami K.; Suzuki N.; Uchide K.; Terada S.; Inoue M.

Transdermal or oral 17-estradiol on plasma lipid profiles; a controlled study
pp. 103-103(1)
Authors: Berg G.; Bjork G.; Hammar M.; Hellberg E.; Lindgren R.; Nordling G.; Ruud T.; Norsdal W.; Gjertsen B.

Plasmatic apolipoproteins and lipidic composition of lipoproteins in pre and postmenopausal women
pp. 103-103(1)
Authors: Berg G.; Halperin H.; Vilarino A.; Lopez G.; Tempone A.; Wilkinski R.

A beneficial rise in HDL cholesterol by lower frequency of NETA administration in sequential HRT
pp. 103-104(2)
Authors: van der Mooren M.J.; Demacker P.N.M.; Schijf C.P.T.; Girardin-v.d. Klaauw C.C.A.M.; Rolland R.

HRT and CVD: progestin induced chances in lipid metabolism may be counterbalanced by a long-cycle strategy
pp. 104-104(1)
Authors: Andersen L.F.; Skouby S.O.; Petersen K.R.; Jespersen J.

Do women's premenstrual symptoms and their mother's climacteric history predict their own vasomotor symptoms?
pp. 104-104(1)
Authors: Wyon Y.A.; Nedstrand E.E.; Skarsgard C.A.; Bjors E.A.; Hammar M.L.

Hot flushes, menstrual status and hormone levels in a population-based sample of Australian-born midlife women
pp. 105-105(1)
Authors: Guthrie J.; Dennerstein L.; Hopper J.; Burger H.

Hormone replacement therapy and psychological symptoms: a comparison of tibolone and conjugated oestrogens
pp. 105-105(1)
Author: Alder E.M.

Improvement of climacteric symptoms prior to HRT
pp. 105-105(1)
Authors: Oldenhave A.; Scholten P.C.; Euser R.; Boon J.

Menopausal symptoms and general well-being: the effect of hormone replacement therapy in 2 groups of Chinese women
pp. 105-105(1)
Authors: Tang G.; Yip P.; Li B.

Postmenopausal symptoms in estrogen treated and non treated women in three age groups
pp. 106-106(1)
Authors: Stenberg A.; Heimer G.; Ulmsten U.

Metabolic risk markers in postmenopausal women with coronary heart disease
pp. 106-106(1)
Authors: Stevenson J.C.; Spencer C.; Godsland I.; Sontag G.; Beale C.; Collins P.

Multicentre evaluation of 17- oestradiol and dydrogesterone HRT on cardiovascular risk
pp. 106-106(1)
Author: Crook D.

The menopausal transition and cardiovascular risk factors
pp. 106-106(1)
Authors: Green A.; Dudley E.; Guthrie J.; Dennerstein L.; Hopper J.; Burger H.

Continuous oestrogen/progestogen HRT and novel mechanisms by which the risk of CHD may be reduced
pp. 107-107(1)
Authors: Ahmed A.; Proudler A.; Crook D.; Rymer J.; Stevenson J.

Metabolic effects of estradiol-norethisterone acetate treatment in postmenopausal women
pp. 107-107(1)
Authors: Falkeborn M.; Naessen T.; Persson I.

Hormone replacement therapy improves glucose metabolism and plasma lipids in postmenopausal women with non-insulin dependent diabetes mellitus
pp. 107-107(1)
Authors: Andersson B.; Mattsson L.; Hahn L.; Marin P.; Lapidus L.; Bengtsson B.; Holm G.; Bjorntorp P.

Role of socio-cultural factors in menopause management
pp. 107-107(1)
Authors: Meschia M.; Bolis P.; Bonaccorsi G.; Cappagli B.; Colacurci N.; Giulini N.

The impact of hormone replacement therapy on quality of life and willingness to pay
pp. 108-108(1)
Authors: Strand R.T.; Henriksson P.; Zethraeus N.; Johannesson M.

Hormone replacement therapy and previous use of oral contraceptives among swedish women
pp. 108-108(1)
Authors: Brynhildsen J.O.; Dabrosin C.L.; Frisk J.; Lindgren R.; Nedstrand E.E.; Wyon Y.A.; Hammar M.L.

Experiences of menopause amongst Greek-speaking women in an Australian city
pp. 108-108(1)
Authors: Kafanelis B.; Black C.; Cable V.; Daly J.; Komesaroff P.A.

Factors associated with health care utilisation during the menopausal transition: a longitudinal study
pp. 109-109(1)
Authors: Donnelly V.; Guthrie J.; Garamszegi C.; Dennerstein L.

Survey of patients attitudes towards attending a menopause clinic
pp. 109-109(1)
Authors: Molloy M.E.; Baber R.J.

Effects of 3 months low-dose HRT on parameters of cardiac function in postmenopausal women
pp. 109-109(1)
Authors: Mijatovic V.; van Baal W.M.; Kamp O.; van der Mooren M.J.; Temmink-van der Hulst C.M.; Voetberg G.A.; Visser C.A.; Kenemans P.

Systemic hemodynamic changes during unopposed and combined hormone replacement therapy (HRT)
pp. 110-110(1)
Authors: Lugones L.; Alfie J.; Belardo A.; Tutzer M.; Galarza C.; Waisman G.; Camera M.

Relationship between climacteric symptoms and impaired coronary blood flow, estimated by ECG-triggered magnetic resonance phase mapping
pp. 110-110(1)
Authors: Sorensen M.; Hansen T.; Ottesen B.

The effects of acute 2 mg sublingual 17-estradiol on exercise induced coronary ischemia in older women with coronary artery disease
pp. 110-110(1)
Authors: Landgren B.; Al-Khalili F.; Eksborg S.; Schenck-Gustafsson K.

How does estrogen replacement therapy affect cardiac function of flushers and non-flushers
pp. 111-111(1)
Authors: Beljic T.; Prelevic G.M.

Reduction in serum VEGF levels in oophorectomised women treated with transdermal oestrogen
pp. 111-111(1)
Authors: Akkad A.A.; Habiba M.A.; Bell S.C.; Al-Azzawi F.

Bone loss in postmenopausal women after renal transplantation: HRT versus calcitriol treatment
pp. 111-111(1)
Authors: Ciammella M.; Eid P.; Aroldi A.; Nencioni T.

Comparison of two doses of conjugated estrogen on postmenopausal bone loss in the lumbar spine assessed by DXA
pp. 111-112(2)
Authors: Soda M.; Mizunuma H.; Okano H.; Kagami I.; Miyamoto S.; Tokizawa T.; Honjo S.; Ibuki Y.

The influence of dietary calcium intake on lumbar bone mineral density under estrogen/gestagen and/or viatmin D3 treatment
pp. 112-112(1)
Authors: Iwaoki Y.; Tamaki M.; Ohama K.

Assessment of bone loss in post menopausal women with hormone replacement therapy by urinary markers of C-telopeptide I collagene. A longitudinal study
pp. 112-112(1)
Authors: Tabaste J.L.; Chebroux P.; Magendie; Berthet J.; Negrier F.; Vendittelli F.; Fignon A.

Stimulatory effect of percutaneous dehydroepiandrosterone (DHEA) on bone mineral density in the rat
pp. 112-112(1)
Authors: Luo S.; Labrie F.

Antiresorptive effect of transdermal estradiol on bone mass in healthy, osteoporotic and fractured postmenopausal women
pp. 113-113(1)
Authors: Moskovic T.; Runic S.; Vukasinovic Z.

Norethisterone and progesterone are potent comparable inducers of endometrial PAI-1 activity
pp. 113-113(1)
Authors: Bertil C.; Tove H.; Goran S.

Tibolone in climacterium: effect on the uterine endometrium of postmenopausal women
pp. 113-113(1)
Authors: Klearchou N.; Kanellaki-Kyparissi M.; Karaviannis V.; Koliakou K.; Vlassis G.; Kalogeropoulos A.

Perimenopausal endometrium: irregular histologic development
pp. 113-113(1)
Authors: Boon J.; vdPutte B.; Heintz A.; Scholten P.; Euser R.; Oldenhave A.

Management of endometrial polyps in menopause patients under HRT
pp. 114-114(1)
Authors: Maia H.; Marques D.; Filho L.C.; Coutinho E.M.

Summary of combined data on endometrial safety considering the enpoint hyperplasia in postmenopausal women taking sequential, combined estradiol and dydrogesterone (femoston)
pp. 114-114(1)
Author: Bergeron C.

Bleeding pattern in HRT regimens with continuous estradiol valerate (EV) and sequential chlormadinone acetate (CMA)
pp. 114-114(1)
Authors: Graser T.; Mellinger U.; Muller A.; Mueck A.O.; Lippert T.H.; Oettel M.

Continuous premarin and medroxyprogesterone acetate vs Tibolone (livial): a comparative study of effects on carbohydrate metabolism, safety, and acceptability - an interim report
pp. 114-115(2)
Authors: Gross B.; Smith H.; Burnett L.; Thompson W.; Jonasson D.; Tamsen L.; Wolter-Svennsonn L.

A cohort study of hormone replacement therapy given to women previously treated for breast cancer
pp. 115-115(1)
Authors: Dew J.E.; Eden J.A.; Bellar E.; Magarey C.J.; Schwartz P.; Crea P.; Wren B.G.

A controlled trial of isoflavones for menopausal symptoms
pp. 115-115(1)
Authors: Eden J.; Knight D.; Howes J.; Mackey R.

Sleep disturbances in post-menopausal women
pp. 115-115(1)
Authors: Lorrain J.; Petit D.; Denesle R.; Montplaisir J.

Does hormone replacement therapy (HRT) have a mood elevating effect in asymptomatic menopausal women?
pp. 116-116(1)
Author: Ross L.A.

Long-term effect of elcatonin on lumbar BMD in postmenopausal women
pp. 117-117(1)
Authors: Wu Y.Y.; Sun C.T.; Cai H.J.

Bone mass is increased by tibolone in postmenopausal women with previous fractures
pp. 117-117(1)
Authors: Studd J.; Arnala I.; Zamblera D.; Kroger H.; Holland N.

Results of the osteoporosis health beliefs scale (OHBS) baseline assessment from a phase III randomized clinical trial of selective estrogen receptor modulator compared with hormone replacement therapy
pp. 117-117(1)
Authors: Houpt L.S.; Minshall M.E.; Grainger D.; Huster W.J.; Kopetsky M.G.; Obenchain R.L.; Muchmore D.B.; Kim K.K.

A clinical trial on the effects of a combination of estrogens and Vit.D₃ on bone loss in pre- and post-menopausal women.
pp. 117-117(1)
Author: Tamura I.

Changes in bone collagen markers in untreated oestrogen treated postmenopausal women.
pp. 118-118(1)
Authors: Brincat M.P.; Galea R.; Baron Y.M.

Changes of bone metabolism and bone density in ovarectomized women in fertile age treated with estradiol valerate and levonorgestrel
pp. 118-118(1)
Authors: Zivny J.; Jenicek J.; Kocian J.; Vinglerova H.

Effect of medrogestone in the maintenance of bone density of surgically-menopausic women using oral and transdermal-estrogen substitutive therapy.
pp. 118-118(1)
Authors: Guinot M.; Saiz M.; Roca B.; Armengol J.; Rodriguez-Espinosa J.; Farrerons J.; Calaf J.

Effect of hormonal replacement therapy (HRT) by oral or transdermal route in the maintenance of bone density in postmenopausal women.
pp. 118-118(1)
Authors: Guinot M.; Pascual E.; Queralto J.M.; Farrerons J.; Calaf J.

Comparison of the effect of divigel, a percutaneous estradiol gel and estraderm (TTS) treatment on total body bone mineral density and lipid metabolism in menopause
pp. 119-119(1)
Authors: Kivinen S.; Hirvonen E.; Wilen-Rosenqvist G.; Kanta-Hame

Conjugated estrogen at a daily dose of 0.625 mg and 0.3 mg had almost the same impact on the changes of bone mineral density and bone metabolism in postmenopausal women.
pp. 119-119(1)
Authors: Chen J.T.; Hasumi K.; Ogata E.

Effect of 12-month DHEA replacement therapy on bone mineral density in 60- to 70-year-old women
pp. 119-119(1)
Authors: Labrie F.; Diamond P.; Cusan L.; Gomez J.L.; Belanger A.

Long term effects of kliogest(R) (kliofem(R)) on bone turnover in postmenopausal women
pp. 119-119(1)
Authors: Hart D.M.; Farish E.; Ekevall K.; Brown A.; Nolan D.; Spowart K.

Oral versus transdermal estrogen: effects on postmenopausal bone loss.
pp. 120-120(1)
Authors: Bruschi F.; Meschia M.; Perotti D.; Rossi M.; Bologna E.; Pifarotti P.

Prevention of osteoporosis with estradiol valerate and cyproteronacetat in postmenopausal women
pp. 120-120(1)
Authors: Felsenberg D.; Halder G.; Leo-Robszberg; Lubbert H.

Integrated management of postmenopausal osteoporosis in a regional centre in hungary
pp. 120-120(1)
Authors: Balogh A.; Bettembuk P.; Bacsko G.; Jakab A.

Positive results of tibolone combined with sodium fluoride in the treatment of postmenopausal osteoporosis
pp. 120-121(2)
Authors: Avramides A.; Tsimpos S.; Triantafyllidou E.; Saddic G.; Kita M.; Somali M.; Haddad J.; Papadopoulou E.; Delaroudis S.

Effects on lipids and bone of 20 years postmenopausal HRT with the synthetic oestrogen, mestranol, followed by 2 years with oestradiol
pp. 121-121(1)
Authors: Farish E.; Hart D.M.; Barnes J.F.; Fletcher C.D.

Comparison of bone mineral density changes of a transdermally administratred 17-estradiol combined with different progestagens. A case-control study.
pp. 121-121(1)
Authors: Pornel B.; Florquin M.; Bastaens R.; Pint A.

Use of nasal calcitonin in severe osteoporotic post menopausal women: metabolic action, bone density fluctuations, possible prevention of future fractures
pp. 122-122(1)
Authors: David A.; Rikover M.; Matas Z.

Clinical and metabolic aspects of postmenopausal women treated with tibolone
pp. 122-122(1)
Authors: Wehba S.; Fernandes C.E.; Ferreira J.A.S.; Aldrighi J.M.; Baracat E.C.; Melo N.R.; Hegg R.

Evaluation of bone turnover biochemical markers and bone density during treatment of postmenopausal osteoporosis with transdermal estrogen.
pp. 122-122(1)
Authors: Kaminski K.; Adamiec D.; Glowacki J.

Evolution of the effect of hormonal replacement therapy in bone mineral density in postmenopausal women.
pp. 122-122(1)
Authors: Castelo-Branco C.; Figueras F.; Sanjuan A.; Pons F.; Vanrell J.A.

Bone mineral density in spontaneous and surgically postmenopausal women receiving hormonal replacement therapy.
pp. 123-123(1)
Authors: Castelo-Branco C.; Sanjuan A.; Figueras F.; Pons F.; Vanrell J.A.

Physical activities of women in the menopause
pp. 123-123(1)
Authors: Vagic N.; Potrebica S.; Vagic D.; ''Novi Zagreb'' D.Z.; Zagreb

Does HRT in pre-menopausal women improve bone density and bone turnover markers
pp. 123-123(1)
Authors: Orr M.; Penny G.; Anderson M.; Robins S.P.; Jandial; Reid D.M.

HRT does not obtain bone metabolism response in each and every case
pp. 123-123(1)
Authors: Ohta H.; Makita K.; Takamatsu K.; Fuyuki T.; Sugimoto I.; Horiguchi F.; Nozawa S.

Concentrations of procollagen type I C-peptide and Gla-osteocalcin in normal and osteoporetic women during hormone replacement therapy
pp. 124-124(1)
Authors: Klinga K.; Salbach B.; Holst T.v.; Runnebaum B.

Determination of bone resorption in postmenopausal women by four bio-markers at urine
pp. 125-125(1)
Authors: Gulbaba R.G.; Gulbaba J.T.A.

Rapid bone loss in oophorectomized thai women
pp. 125-125(1)
Authors: Taechakraichana N.; Limpaphayom K.; Jaisamrarn U.; Poshyachinda M.

The present state of the special out-patient ward (the menopause ward) in our hospital
pp. 125-125(1)
Authors: Komai H.; Taniguchi S.

Quantttative ultrasound sonography at the calcaneus in gynaecology. A new promising method
pp. 125-125(1)
Authors: Hadji P.; Bohnet H.

Premature osteoporosis in women with crohn's disease (CD)
pp. 126-126(1)
Authors: Al-Azzawi F.; Robinson R.J.; Mayberry J.F.

The health impact of self referral bone densitometry
pp. 126-126(1)
Authors: Kennedy R.G.; Snow A.; Al-Azzawi F.

Bone mass density and mechanical properties of forearms of women in peri and postmenopausal period affected by colles fractures
pp. 126-126(1)
Authors: Bienkowska R.; Talajko A.; Hoszowski K.; Lorenc R.S.

Bone mineral density in postpartum women
pp. 126-126(1)
Authors: Honda A.; Yahata T.; Tojo Y.; Kurabayashi T.; Tanaka K.

Pattern of surgical menopausal bone loss
pp. 127-127(1)
Authors: Chittacharoen A.; Theppisai U.; Sirisriro R.; Thanantaseth C.

Bone mineral density levels and T-YOUNG SCORE (SD) related to femur fracture in a group of postmenopausal women
pp. 127-127(1)
Authors: Russo L.A.; Gregorio L.H.; Martins S.R.; Cox A.T.

Tibial ultrasound velocity in women with polycystic ovary
pp. 127-127(1)
Authors: Hsu C.-C.; Wu M.-H.; Huang K.-E.

Prevalence of vertebral osteoporosis in relation to its risk factors in random sample of post-menopausal women
pp. 127-127(1)
Authors: Czekalski S.; Miazgowski T.; Krzysztalowski A.; Napierala K.

Does low bone mineral density in anorexia nervosa depend on secondary amenorrhea duration?
pp. 128-128(1)
Authors: Krzyzanowska B.; Miazgowski T.; Gulinska M.; Czekalski S.

Tea consumption and bone mineral density in postmenopausal women
pp. 128-128(1)
Authors: Celikkanat H.; Gokmen O.; Gulerman C.; Moroy P.; Tan M.; Ozaksit G.

Bone mineral content of postmenopausal women with leiomyoma uteri
pp. 128-128(1)
Authors: Moroy P.; Gokmen O.; Gulerman C.; Celikkanat H.; Doganay M.; Oransay S.

An epidemiologic study of the bone mineral status of Turkish women
pp. 128-128(1)
Authors: Moroy P.; Gulerman C.; Alaybeyoglu L.; Cetindag I.; Selam B.; Gokmen O.

Correlation between mineral density of each lumbar vertebral bone and age in pre- and postmenopausal women
pp. 129-129(1)
Authors: Ishikawa K.; Watanabe R.; Yoshinaka A.; Mori T.; Kumasaka T.; Inaba N.

The effect of body weight on mineral density of each vertebral bone with in perimenopausal women
pp. 129-129(1)
Authors: Ohtsuka S.; Kumasaka T.; Ishikawa K.; Watanabe R.; Mori T.; Inaba N.

Markers of collagen biosynthesis and degradation during hormonal replacement therapy
pp. 129-129(1)
Authors: Jakowicki J.A.; Rechberger T.; Skorupski P.; Czarnacki J.; Postawski K.

Classification of lumbar vertebral type based on bone mineral density and its clinical significance
pp. 130-130(1)
Authors: Watanabe R.; Isikawa K.; Yoshinaka A.; Mori T.; Kumasaka T.; Inaba N.

Menopause clinic - compliance on HRT
pp. 131-131(1)
Authors: Beljic T.; Zivanovic D.

Hormone replacement therapy (HRT): a comparison of informed decision making and patient satisfaction in a traditional office visit versus a group visit
pp. 131-131(1)
Authors: Blomo C.S.; Dyer W.Z.

Prophylaxis programme of menopausal and post menopausal disorders in women in the Gdansk region
pp. 131-131(1)
Authors: Szczurowicz A.; Wojcikowski C.; Szymula J.; Szuczurowicz A.; Lukaszuk K.

The role of the community pharmacist in HRT monitoring
pp. 132-132(1)
Authors: Tanna N.K.; Pitkin J.

Monitoring of patients on hormone replacement therapy (HRT) within the primary care setting
pp. 132-132(1)
Authors: Tanna N.K.; Pitkin J.

Audit of general practitioner (GP) referrals to hospital based menopause clinic
pp. 132-132(1)
Authors: Sethi K.K.; Pitkin J.

The Jean Hailes foundation - women's health education program as a reproducible model
pp. 132-132(1)
Authors: Davidson G.A.; Michelmore J.H.; Craven R.; Davis S.R.

Mid life health survey of medical graduates from 1975
pp. 133-133(1)
Authors: Murkies A.L.; Farrell E.A.

What is involved in co-ordinating and implementing a multicentre hormone replacement therapy (HRT) clinical trial? - An Australian perspective
pp. 133-133(1)
Authors: Hangan J.T.; Gordon J.A.; Leahy F.C.; Penon D.M.; Moreton T.; Detmold N.; Cooper J.; Wenzel S.; Ingham M.

Prevalence of hormone replacement therapy in menopausal women
pp. 133-133(1)
Authors: Gulerman C.; Gokmen O.; Celikkanat H.; Moroy P.; Alaybeyoglu L.; Doganay M.; Sener B.

Compliance with hormone replacement therapy in women attending a menopause clinic
pp. 134-134(1)
Authors: Molloy M.E.; Baber R.J.

Association of the 3-adrenergic receptor gene TRP64ARG mutation with weight, body mass index, abdominal fat, blood pressure and reproduction
pp. 135-135(1)
Authors: Kurabayashi T.; Carey D.G.P.; Morrison N.A.

Serum and fatty tissue dehydroepiandrosterone (DHEA) concentrations in obese pre - and postmenopausal women
pp. 135-135(1)
Authors: Milewicz A.; Szymczak J.; Guglas E.

Estradiol or tibolone administration increases GH secretion in postmenopausal women
pp. 135-135(1)
Authors: Genazzani A.; Sgarbi L.; Gamba O.; Gastaldi M.; Petraglia F.; Volpe A.

HRT in renal transplant recipients evaluation of effectiveness and safety - preliminary data
pp. 135-135(1)
Authors: Pietrzak B.; Boszko B.K.; Gradowska L.; Marianowski L.

Five years therapy of HRT and the effect on body mass index
pp. 136-136(1)
Authors: Rymer J.; Robinson J.; Darke K.; Moncrieff M.; Fogelman I.

Neuroendocrine control of thyroid function during aging in women
pp. 136-136(1)
Authors: Rossmanith W.G.; Stabler C.

Ageing, menopausal therapy and kidney function
pp. 136-136(1)
Authors: Ginsburg J.; Prelevic G.M.; Kicovic P.M.

Effects of tibolone on diabetic control and serum lipids in postmenopausal women with non-insulin dependent diabetes mellitus
pp. 137-137(1)
Authors: Prelevic G.M.; Beljic T.; Balint-Peric L.; Ginsburg J.

Comparative assessment of endocrinologic stimulation tests (TRH; GH-RH) with patients at fertile age and climacteric patients
pp. 137-137(1)
Authors: Jirecek S.G.; Knogler W.E.; Sator M.O.; Blaicher W.A.; Hauk R.G.; Fischl F.H.; Huber J.C.

Anthropometric measurement by means of dual-energy-x-ray absorptiometry in menopausal women
pp. 137-137(1)
Authors: Gruber D.M.; Schatten C.; Sator M.O.; Frigo P.

The effect of klimonorm on liver function and the menopausal syndrome
pp. 137-137(1)
Author: Szlachcic M.J.

The effects of long term oestrogen on body fat distribution and lipid profiles
pp. 138-138(1)
Authors: Calder A.L.; Ramsay J.; Farish E.; Hart D.M.

The effect of menopause on serum uric acid levels in non-obese healthy women
pp. 138-138(1)
Authors: Wingrove C.S.; Walton C.; Stevenson J.C.

Weight gain and hormone replacement therapy: an educational approach to patient concerns
pp. 138-138(1)
Authors: Lanzarone V.F.; Preistly D.; Chippindall M.J.; Dunsmore J.; Levido J.; Baber R.

A comparison of the levels of immunoreactive inhibin and dimeric inhibin A in perimenopausal women
pp. 138-139(2)
Authors: Burger H.G.; Cahir N.; Robertson D.M.; Groome N.P.; Dudley E.; Green A.; Hopper J.; Dennerstein L.

The effects of oral oestradiol with either sequential or continuous NETA on glucose and insulin responses to ₀GTT in postmenopausal women
pp. 139-139(1)
Authors: Balint-Peric L.A.; Beljic T.; Prelevic G.M.

The effects of hormone replacement therapy (HRT) on exercise performance in postmenopausal women
pp. 139-139(1)
Authors: Stojanovska L.; Selig S.; Cary S.; Martin I.; Craven R.

The prevalence and assessment of abnormal thyroid function tests in postmenopausal women not taking hormone replacement
pp. 139-139(1)
Authors: Bozich T.; Stuckey B.; Coulden S.; Gutteridge D.; Bhagat C.; Evans D.; Keogh E.

A comparative study of the effect of Kliogest and livial on carbohydrate metabolism in post-menopausal women
pp. 140-140(1)
Authors: Joyce M.; O'Keeffe N.; Norris L.A.; Sheppard B.L.; Bonnar J.

Surveillance of menopausal women during HRT
pp. 140-140(1)
Authors: Boschitsch E.; Endler T.; Bieg1mayer C.

Smoking influence on oestrogen levels of postmenopausal women in hormonal replacement therapy
pp. 140-140(1)
Authors: Wehba S.; Fernandes C.E.; Machado R.B.; Azevedo L.H.; Ferreira J.A.S.

Inhibin B concentrations in the menopausal transition
pp. 140-141(2)
Authors: Illingworth P.; Klein N.; Cawood E.; Groome N.; Bancroft J.; Soules M.; McNeilly A.

The estimation of estracomb TTS influence on chosen biochemical parameters of carbohydrate, fat and hormonal metabolism
pp. 141-141(1)
Authors: Poreba R.; Ciszek V.

Serum galanin, cholecystokinin, NPY and beta-endorphin (-EP) in menopausal women with different history of obesity
pp. 142-142(1)
Authors: Milewicz A.; Bidzinska B.; Mikulski E.

The establishment of sensitive measurement of PTH receptor mRNA using competitive PCR with internal standard
pp. 142-142(1)
Authors: Miyamoto S.; Kagami I.; Soda M.; Okano H.; Tokizawa T.; Mizunuma H.; Ibuki Y.; Uchida T.

Norethindrone acetate (NETA) enhances the antiatherogenic effect of 17-estradiol (E₂) in ovariectomized cholesterol-fed rabbits
pp. 143-143(1)
Authors: Alexandersen P.; Haarbo J.; Sandholdt I.; Lawaetz H.; Christiansen C.

The involvement of IL-6 receptor and GP130 in osteoclast differentiation and function in postmenopause
pp. 143-143(1)
Authors: Gao Y.; Morita I.; Maruo N.; Kubota T.; Murota S.; Aso T.

In vitro investigations on the calcium-blocking effect of estrogens and progestogens
pp. 143-143(1)
Authors: Mueck A.; Seeger H.; Lippert T.

Bioavailability of percutaneously administered dehydroepiandrosterone in the rat
pp. 143-143(1)
Authors: Labrie C.; Flamand M.; Belanger A.; Labrie F.

The effect of ovarian hormone on the bone loss in oophorectomized rats
pp. 144-144(1)
Authors: Kasai Y.; Nakazawa N.; Yano T.; Sagara Y.; Doi M.; Kunioka M.; Taketani Y.

Mib 1 and bcl-2 immunohistochemistry - a basis for a reproducible evaluation of the endometrium during HRT
pp. 144-144(1)
Authors: Karlsson K.; Risberg B.; Lagrelius A.

Levormeloxifene, a non-steroidal estrogen receptor therapeutic, prevents bone loss, reduces serum cholesterol, and has differentiated uterine, 'effects in the ovariectomized rat
pp. 144-144(1)
Authors: Bain S.; Shalmi M.; Korsgaard N.

Levormeloxifene, a non-steroidal estrogen receptor therapeutic, mimics estrogen effects on expression of tartrate resistant acid phosphatase, carbonic anhydrase-II, and estrogen receptor in ovariectomized rats
pp. 145-145(1)
Authors: Wassermann K.; Bain S.

Levormeloxifene, a non-steroidal estrogen receptor therapeutic, exerts a non-proliferative action on uterine tissues of the ovariectomized rat
pp. 145-145(1)
Authors: Korsqaard N.; Kurman R.; Greenspan D.L.; Bain S.

Influence of oestrogen-only hormone replacement therapy on blood angiotensin I-converting enzyme activity
pp. 146-146(1)
Authors: Proudler A.; Stevenson J.; Cooper A.; Ross D.; Whitehead M.

Physiological dose of estrogen regulates extrathymic T cells in female mice
pp. 146-146(1)
Authors: Yahata T.; Kurabayashi T.; Honda A.; Tojo Y.; Tanaka K.; Abo T.

Levormeloxifene, a non-steroidal partial oestrogen receptor agonist, is a vasodilator in vivo and in vitro
pp. 146-146(1)
Authors: Shalmi M.; Sheardown M.; Weis J.U.; Bain S.D.; Guldhammer B.; Korsgaard N.

Background of aging change in arterial wall: intimal hyperplasia with the impaired synergism between PG12 and nitric oxide in human uterine arteries before menopause
pp. 147-147(1)
Authors: Obayashi S.; Hamasaki H.; Sato J.; Koyama T.; Azuma H.; Aso T.

Estrogen effect on expression of mRNA of PDGF-, IL-1 and IL-6 in human umbilical venous endothelial cells
pp. 147-147(1)
Authors: Tsuchiya H.; Urabe M.; Yokota K.; Okubo T.; Iwasa K.; Kikuchi N.; Yamamoto T.; Honjo H.

Direct atheroprotective effect of estrogen on human smooth muscle cells and endothelial cells
pp. 147-147(1)
Authors: Urabe M.; Tsuchiya H.; Okubo T.; Iwasa K.; Yokota K.; Kikuchi N.; Honjo H.

The effects of 17- estradiol, medroxyprogesterone acetate and parathyroid hormone on akaline phosphatase activity in the osteoblastic cell line ROS 17/2.8-5
pp. 147-147(1)
Authors: Cho S.H.; Kim K.J.; Lee J.A.; Moon H.; Hwang Y.Y.

Estradiol inhibits the voltage-dependent Ca channels of the rabbit basilar artery through GTP-binding protein
pp. 148-148(1)
Authors: Ogata R.; Nozaki M.; Inoue Y.; Hashimoto K.; Sano M.; Nakano H.

Estradiol relaxes the rabbit basilar artery through voltage-dependent Ca channels
pp. 148-148(1)
Authors: Hashimoto K.; Ogata R.; Nozaki M.; Inoue Y.; Sano M.; Nakano H.

Women referred to a specialist menopause clinic with premature ovarian failure
pp. 149-149(1)
Authors: Birdsall M.A.; Rees M.

The characteristic of the decreased bone mass in premature ovarian failure
pp. 149-149(1)
Authors: Lin S.O.; He F.F.; Lin Y.; Zhang T.; Yu W.; Ge Q.S.

Oestrogen deprivation at puberty a case presentation
pp. 149-149(1)
Author: Jan W.J.

Effects of HRT in the early menopause
pp. 149-149(1)
Authors: Bris J.M.; Peramo B.; Munoz E.; Diaz S.; Ordonez D.; Pascual M.; Rey M.; de la Fuente P.

Tibial ultrasound velocity in women with premature ovarian failure
pp. 150-150(1)
Authors: Huang K.-E.; Wu M.-H.; Hsu C.-C.

The use of 20MHz ultrasound for assessing the efficacy of HRT on the skin
pp. 151-151(1)
Authors: Cheung L.; Rymer J.; Robinson J.; Dyson M.; Young S.R.

Efficacy and skin irritation with two forms of transdermal estrogen therapy
pp. 151-151(1)
Authors: Backstrom A.-C.; Hirvonen E.; Kivinen S.

Dermatological changes associated with hormonal environment in perimenopausal Japanese women
pp. 151-151(1)
Authors: Makita K.; Ohta H.; Kawashima T.; Kinoshita S.; Takamatsu K.; Horiguchi F.; Takenouchi M.; Nozawa S.

The effect of sex steroids on uterine artery blood flow in menopausal women: a preliminary report
pp. 152-152(1)
Authors: Baziad A.; Wiknjosastro G.; Salim A.; Jacoeb T.; Karsono B.; Lazuardi

The influence of long-term HRT on ambulatory bloodpressure in older women with coronary artery disease
pp. 152-152(1)
Authors: Pripp U.M.; Hall G.; Landgren B.-M.; Schenck-Gustafsson K.

Haemostatic risk factors in postmenopausal women (postmw) and their vascular implications
pp. 152-152(1)
Authors: Vilarino A.; Scazziota A.; Tempone A.; Jacquier G.; Raimondi R.; Pons S.; Penalva L.; DiPaola G.

The effect of transdermal estro-progestogen therapy on cardiovascular hemodynamic in healthy postmenopausal women
pp. 153-153(1)
Authors: Bohdanowicz-Pawlak A.; Salomon P.; Kosmala W.; Bednarek-Tupikowska G.; Milewicz A.; Lewinski A.

Coagulation and fibrinolysis in postmenopausal women during hormonal replacement therapy (transdermal estradiol/medroxyprogesterone acetate oraly)
pp. 153-153(1)
Authors: Ciepluch R.; Czestochowska E.

Cardiovascular risk factors and BMD changes during micronized 17estradiol and dydrogesterone oral therapy in postmenopausal women: a three-year prospective study:
pp. 153-153(1)
Authors: Palacios S.; Menendez C.

The effect of tibolone on heart function of postmenopausal women with NIDDM
pp. 153-153(1)
Authors: Beljic T.; Prelevic G.M.

HRT decreases coronary artery calcification
pp. 154-154(1)
Authors: Shemesh J.; Frenkel Y.; Leibovitch L.; Grossman E.; Pines A.; Segev S.; Itzchak Y.; Motrol M.

Carotid artery wall correlates with skin thickness in postmenopausal women
pp. 154-154(1)
Authors: Baron Y.M.; Brincat M.P.; Galea R.

Carotid artery wall thickness in postmenopausal women treated with hormone replacement therapy
pp. 154-154(1)
Authors: Baron Y.M.; Brincat M.P.; Galea R.

Impaired ovarian function as a risk factor for atherosclerosis in premenopausal women
pp. 154-154(1)
Authors: Punnonen R.H.; Jokela H.A.; Aine R.A.; Teisala K.K.; Salomaki A.M.; Uppa H.S.

The effect of HRT on uterine arterial blood flow in postmenopausal women assessed by transvaginal color doppler sonography (TVDS)
pp. 155-155(1)
Authors: Omodei U.; Ruggeri C.; Palai N.; Fallo L.; Boccuti A.M.; Dordoni D.

Effects of low-dose HRT on arterial elasticity and flow-mediated endothelium-(in)dependent vasodilation in postmenopausal women
pp. 155-155(1)
Authors: van Baal W.M.; Lambert J.; Aarsen M.; Mijatovic V.; Peters-Muller E.R.A.; Voetberg G.A.; van der Mooren M.J.; Kenemans P.; Stehouwer C.D.A.

The effects of changing from mestranol to 17-beta oestradiol on blood coagulation and fibrinolysis in post menopausal women
pp. 155-155(1)
Authors: Cumming G.; Spowart K.; Hart D.M.

The effect of postmenopausal hormone replacement therapy on blood pressure in the short term
pp. 156-156(1)
Authors: Grassini E.; Duca G.; Radici G.; Hanozet F.; Capetta P.

Effects of hormone replacement therapy on pulse wave velocity in postmenopausal women
pp. 156-156(1)
Authors: Nakagawa H.; Sanada M.; Ohama K.

The influence of hormone replacement therapy on the thickness of carotid artery wall in postmenopausal women: measurement with a high-frequency ultrasonography unit
pp. 156-156(1)
Authors: Sator M.O.; Gruber D.M.; Jirecek S.G.; Thurner N.G.; Fischl F.H.; Huber J.C.

Is the arterial wall composition preserved by estrogens? A comparative study between long-term users, age matched controls and young women
pp. 156-156(1)
Authors: Naessen T.; Rodriguez K.

Compliance with HRT in postmenopausal women with coronary artery disease
pp. 157-157(1)
Authors: Hall G.; Pripp U.; Schenck-Gustafsson K.; Landgren B.-M.

Urinary surrogate-markers for vascular effects of transdermal and oral estradiol in, postmenopausal women
pp. 157-157(1)
Authors: Lippert T.; Seeger H.; Mueck A.

Coadministration of moexipril and hormonal replacement therapy in postmenopausal women
pp. 157-157(1)
Authors: Stimpel M.; Koch B.

Antihypertensive treatment in postmenopausal women: diuretic or ACE inhibitor?
pp. 158-158(1)
Authors: Stimpel M.; Koch B.

Comparison between moexipril and atenolol in obese postmenopausal women with hypertension
pp. 158-158(1)
Authors: Stimpel M.; Koch B.

A new model for induction of intimal hyperplasia in human blood vessels using postmenopausal serum
pp. 159-159(1)
Authors: Al-Azzawi F.; Akkad A.A.

ICAM-1 expression in human blood vessels cultured in postmenopausal serum
pp. 159-159(1)
Authors: Akkad A.A.; Al-Azzawi F.

17-oestradiol inhibits intimal hyperplasia in cultured human blood vessels
pp. 159-159(1)
Authors: Akkad A.A.; Al-Azzawi F.

Bodycomposition in postmenopausal women correlates with cardiovascular parameters estimated by ECG-triggered magnetic resonance phase mapping
pp. 159-159(1)
Authors: Sorensen M.; Hansen T.; Rosenfalck A.; Ottesen B.

Influence of oral gestagen on the effect of transdermal estrogen replacement therapy (ERT) on endothelial dysfunction in postmenopausal women
pp. 160-160(1)
Authors: Haller H.; Thalhammer C.; Wagner K.; Paszfall J.; Nauert C.; Luft F.C.

An open study of the effects of oral 17B oestradiol and oral dydrogesterone on the internal carotid artery pulsatility index in hysterectomised women
pp. 160-160(1)
Authors: Cooper A.; Ross D.; Spencer C.; Marsh M.; Stevenson J.; Whitehead M.

The influence of age and serum oestradiol levels on resistance to blood flow in the internal carotid artery in postmenopausal women
pp. 160-160(1)
Authors: Marsh M.; Ross D.; Stevenson J.; Whitehead M.

Diurnal variation in uterine artery pulsatility index in postmenopausal women using transdermal oestradiol
pp. 161-161(1)
Authors: Ross D.; Jurkovic D.; Godfree V.; Morris K.; Whitehead M.

The influence of hormonal replacement therapy on blood flow
pp. 161-161(1)
Authors: Debski R.; Binkowska M.; Garwolinski J.; Kretowicz P.

Effects of continuous combined estrogen and progestogen replacement therapy on the uterine vasculatur tree of postmenopausal women
pp. 161-161(1)
Authors: Doren M.; der Landwehr U.A.; Schneider H.P.G.

Progestin administration does not attenuate the antioxidant effect of estradiol valerate in postmenopausal women
pp. 162-162(1)
Authors: Doren M.; Schroder J.; Schneider H.P.G.; Oettel M.

Continuous treatment with estradiol and norethisterone actetate and the influence on risk factors for cardiovascular disease
pp. 162-162(1)
Author: Moen M.H.

The influence of progestins on normotensive & hypertensive menopausal women under hormone replacement therapy
pp. 162-162(1)
Authors: Pramparo P.; Urthiague M.; Famiani Z.; Mural J.; Rodriguez V.D.; Balestrini A.

Atherogenic risk: effects of combined continuous oestradiol-medroxyprogesterone administration on plasma lipids, lipoproteins and coagulation profiles
pp. 163-163(1)
Authors: Vidal D.R.; Sermukslis B.; Najum E.; Mollerach M.; Deza E.G.

The relation between hormone replacement therapy and risk factors for cardiovascular disease in postmenopausal women
pp. 163-163(1)
Authors: Traianos B.; Kolitsidakis Y.; Koukouvitis S.; Vlassis G.

Ace inhibitor vs. calcium-antagonist in postmenopausal women: results from the MADAM-program
pp. 163-163(1)
Authors: Prusse D.I.; Stimpel M.

Menopause and impaired endothelial function in Caucasian but not in Chinese women
pp. 164-164(1)
Authors: McCrohon J.; Woo K.; Robinson J.; Celermajer D.

Uterine notching in the menopause reflects the arterial status and the arterial effect of HRT
pp. 164-164(1)
Authors: Jakab A.; Ovari L.; Toth Z.; Balogh A.

Comparison of the effects of oral and transdermal HRT on plasma endothelin-1 and urinary excretion of prostacyclin and thromboxane metabolites
pp. 164-164(1)
Authors: Ylikorkala O.; Cacciatore B.; Paakkari I.; Tikkanen M.J.; Toivonen J.

The influence, of HRT on cardiovascular system in postmenopausal women
pp. 164-164(1)
Authors: Smethic V.; Klimenchenko N.

Premenstrual syndrome and perimenopausal experiences: is there a relationship.
pp. 165-165(1)
Authors: Morse C.A.; Dennerstein L.; Dudley E.; Hopper J.

Sexuality, hormones and the menopausal transition
pp. 165-165(1)
Authors: Dennerstein L.; Dudley E.; Hopper J.; Burger H.

The effect of hormonal replacement therapy on female sexuality in postmenopausal period
pp. 165-165(1)
Author: Borovsky M.

Current opinion about psychological and psychosocial aspects using health questionnaires to maintenance HRT compliance
pp. 165-166(2)
Authors: Frailuna J.P.; Magaril C.

Oestrogen improves dysfunction of the frontocortico-striatal network (FCNS) during menopause
pp. 166-166(1)
Authors: Al-Azzawi F.; Habiba M.A.; Dursun S.M.; Reveley M.A.

Sexual interest of postmenopausal women is associated with 5 alpha-reductase activity
pp. 166-166(1)
Authors: Kennedy R.G.; Davies T.; Al-Azzawi F.

Quality of life of women aged from 45 to 65 years: the ''Bailleul, Femmes dans la Ville'' study
pp. 167-167(1)
Authors: Belaisch J.; Breart G.; Jaudinot E.-O.; Boute D.

Effect of estrogen on senile dementiaalzheimer's type through suppression of apolipoprotein E
pp. 167-167(1)
Authors: Iwasa K.; Urabe M.; Tsuchiya H.; Okubo T.; Yokota K.; Kikuchi N.; Hayashi M.; Hayashi K.; Honjo H.

The characteristics of menopausal patients taking psychiatric help
pp. 167-167(1)
Authors: Ozsahin A.; Avci N.; Gokmen O.

Effects of tibolone on sexuality in postmenopausal women
pp. 168-168(1)
Authors: Wehba S.; Fernandes C.E.; Ferreira J.A.S.; Aldrighi J.M.; Baracat E.C.; Melo N.R.; Hegg R.

Effect of sexual life-a comparison between tibolone and a continuous estradiol-norethisterone acetate regimen
pp. 168-168(1)
Authors: Nathorst-Boos J.; Hammar M.

Clinical and Psychometric studies in menopausal syndrome patients with and without depression
pp. 168-168(1)
Authors: Brandstatter N.; Stamenkovic M.; Saletu B.; Metka M.; Grunberger J.; Huber J.

Changes in the cardiovascular risk profile of postmenopausal women on three-monthly HRT
pp. 169-169(1)
Authors: van der Mooren M.J.; Demacker P.N.M.; Blom H.J.; de Rijke Y.B.; Rolland R.

Beneficial changes in lipoproteins and plasma renin activity during lyrelle 17-E₂ patch (25 cm² and 40 cm²) and estraderm TTS(R) 50 in hysterectomised postmenopausal women
pp. 169-169(1)
Authors: van der Mooren M.J.; Rolland R.; Al-Azzawi F.; Hirvonen E.; Genazzani A.R.; Brincat M.P.

The influence of HRT on lipids and lipoproteins metabolism and selected parameters of coagulation in perimenopausal women.
pp. 170-170(1)
Authors: Gadomska H.; Nowicka G.; Marianowska A.; Wielgos M.; Marianowski L.

Serum lipids and bone mass density before and after hormone replacement therapy
pp. 170-170(1)
Authors: Payer J.; Borovsky M.; Murin J.; Killinger Z.; Ondrejka P.

In vitro effect of estradiol(E₂), progesterone (P) and testosterone (T) on LDL-cholesterol oxidation in postmenopausal women.
pp. 170-170(1)
Authors: Arteaga E.; Rojas A.; Villaseca P.; Bianchi M.; Arteaga A.; Duran D.

Effects of hormone replacement therapy on remnant lipoproteins in menopausal women
pp. 171-171(1)
Authors: Sanada M.; Nakagawa H.; Ohama K.

The effect of HRT on Lp(a) plasma levels
pp. 171-171(1)
Authors: Duenas J.L.; Albert A.; Fabiani F.

The effect of bilateral oophorectomy on Lp(a) plasma levels in postmenopausal women.
pp. 171-171(1)
Authors: Duenas J.L.; Marquez F.; Fabiani F.

Effect of medrogestone over lipid pattern of surgically-menopausic women on oral- and transdermal-estrogen sustitutive therapy.
pp. 171-172(2)
Authors: Guinot M.; Otal C.; Saiz M.; Ordonez J.; Calaf J.

Postmenopausal HRT with oral norethisterone: does the route of administration of the oestrogen influence serum lipoprotein levels?
pp. 172-172(1)
Authors: Crook D.; Ross D.; Cooper A.; Spencer C.; Worthington M.; Whitehead M.; Stevenson J.

Effects of medroxyprogesterone acetate on lipoprotein metabolism in postmenopausal women receiving estrogen
pp. 172-172(1)
Authors: Wakatsuki A.; Morioka N.; Sagara Y.

Effects of hormone replacement therapy on lipoprotein(A) and other lipids
pp. 173-173(1)
Authors: Meschia M.; Bruschi F.; Amicarelli F.; Curtarelli M.; Rossi M.; Pifarotti P.

Impact of combined hormone replacement therapy (HRT) on serum low density lipoprotein (LDL) particle size
pp. 173-173(1)
Authors: Alexandersen P.; Haarbo J.; Christiansen C.

Long-term effects of postmenopausal hormone replacement therapy on serum lipids and lipoproteins
pp. 173-173(1)
Authors: Lahdenpera A.; Luotola H.; Puolakka J.; Pyorala T.; Taskinen M.-R.

Lipid and lipoprotein effects of transdermal and oral oestrogens: a randomised double-blind double-dummy placebo-controlled study
pp. 173-174(2)
Authors: Ross D.; Cooper A.; Spencer C.; Worthington M.; Whitehead M.; Stevenson J.

Influence on lipoprotein and bone metabolism of megestrol acetate, used in the management of symptomatic postmenopausal women
pp. 174-174(1)
Authors: Farish E.; Ekevall K.; Barnes J.F.; Fletcher C.D.; Hart D.M.

Variations of lipids (L) and blood pressure (BP) during combined continuous hormone replacement therapy (CC-HRT) in postmenopausal women (PW)
pp. 174-175(2)
Authors: Martino M.; Vidal D.R.; Paciocco M.; Aguirre M.; Deza E.G.; Mirkin A.

Effect of progestogens on plasma lipids and lipoproteins in postmenopausal women using conjugated estrogens
pp. 175-175(1)
Authors: Takada S.; Teramoto T.; Morita T.; Fukazawa M.; Mori H.

Serum lipid profile of surgical and natural postmenopausal Turkish women
pp. 175-175(1)
Authors: Oransay S.; Gokmen O.; Celikkanat H.; Sener B.; Ozaksit G.; Moroy P.

The effects of hormone replacement therapy on serum concentrations of lipoprotein (a), angiotensin converting enzyme and insulin in postmenopause
pp. 175-175(1)
Authors: Seckin N.; Sener A.; Turhan N.; Gokmen O.; Ozmen S.; Ozturk M.; Kaftanoglu O.

The influence of ovariectomy on serum lipoproteins in postmenopausal women
pp. 176-176(1)
Authors: Jakowicki J.A.; Kotarski J.; Zwolski D.

Beneficial effects of hormone replacement therapy: testosterone in hypogonadal men and estrogen in postmenopausal women on plasma IGF-I, lipids and lipoproteins concentrations
pp. 176-176(1)
Authors: Zgliczynski S.; Slowinska-Srzednicka J.; Brzezinska A.; Ossowski M.; Zgliczynski W.; Jeske W.; Chotkowska E.

Long term hormonal replacement therapy (5 years) and lipid profile changes
pp. 176-176(1)
Authors: Castelo-Branco C.; Figueras F.; Sanjuan A.; Casals E.; Vanrell J.A.

Breast cancer in postmenopausal women: general profile of the patient in our region (Madrid)
pp. 177-177(1)
Authors: Nieto A.; Tacuri C.; Ortega A.; Sanchez S.; Cortes J.

Breast response to hormonal replacement therapy (HRT) in pre- and post-menopausal women with concomitant benign breast disease (BBD)
pp. 177-177(1)
Author: Cupceancu B.

Mammary and metabolic effects related with tamoxifen treatment in postmenopausal women
pp. 177-177(1)
Authors: Perez-Lopez F.R.; Sanz R.P.; Morollon I.; Villavieja L.; Hergueta J.; Bescos J.L.; Juste G.

A menopause oncology clinic: a novel service
pp. 177-177(1)
Authors: Rees M.; Brockie J.; Suffling K.; O'Byrne K.; Harris A.; Clarke P.

Breast and thyroid disease screening for perimenopausal woman by ultrasound
pp. 178-178(1)
Authors: Hachiya T.; Wake N.

Breast self-examination: knowledge and performance among women attending menopause clinic
pp. 178-178(1)
Authors: Poomarporn O.-A.; Theppisai U.

Breast self-examination technique among women attending menopause clinic
pp. 178-178(1)
Authors: Khanacharoen A.; Poomarporn O.-A.; Theppisai U.

Fluid in the uterine cavity in postmenopausal women - the sign of endometrial carcinoma?
pp. 178-178(1)
Authors: Surkont G.; Lech W.; Suzin J.

Results of mammographic screening in menopausal women
pp. 179-179(1)
Authors: Gulerman C.; Moroy P.; Celikkanat H.; Cetindag I.; Alaybeyoglu L.; Oransay S.

Comparison of mamographic findings in asymptomatic patients and cases with breast symptoms
pp. 179-179(1)
Authors: Gulerman C.; Moroy P.; Cetindag I.; Celikkanat H.; Alaybeyoglu L.; Gokmen O.

Oncological aspects of HRT
pp. 179-179(1)
Authors: Szabo B.; Berko P.; Aszodi A.

Laparoscopic colpourethrocystopexi in postmenopausal women
pp. 180-180(1)
Authors: Al-Hijii J.; Persson J.; Iosif C.S.

Urogenital symptoms and resulting discomfort in non-institutionalized Dutch women aged 50 to 75 years
pp. 180-180(1)
Authors: van de Weiler P.; van Geelen J.; Arnolds H.

Clinical and cytovaginal effects of oestriol intravaginally in postmenopausal women with urogenital complaints
pp. 180-180(1)
Author: Lutan D.

Effect of replens-a nonhormonal vaginal moisturizer on vaginal atrophy in breast cancer patients: a cytological study
pp. 180-180(1)
Authors: Raqavan V.V.; Ferenczy A.; Gelfand M.M.

Viral vulvo-vaginitis masquerading as atrophic change in postmenopausal women
pp. 181-181(1)
Authors: Cooper A.; Lawton F.; Whitehead M.I.

Does smoking induce vaginal maturity?
pp. 181-181(1)
Authors: Nilsson K.E.; Heimer G.M.; Risberg B.; Hanson U.

Clinical trial of vaginally administered conjugated estrogens and tibolone in postmenopausal women
pp. 181-181(1)
Authors: Botsis D.; Kalogirou D.; Kassanos D.; Antoniou G.; Kalogirou O.

The effect of oestrogen and vitamin E treatment on the maturation index of cervicovaginal smear
pp. 181-181(1)
Authors: Doganay M.; Gulerman C.; Celikkanat H.; Zergeroglu S.; Alaybeyoglu L.; Gokmen O.

Cervical displasia in postmenopausal women
pp. 182-182(1)
Authors: Ozaksit G.; Sener A.B.; Kuscu E.; Seckin N.C.; Oransay S.; Celikkanat H.; Moroy P.; Gokmen O.

Associated factors to urinary and genital symptoms prevalence in climateric and postmenopausal women
pp. 182-182(1)
Authors: Guarisi T.; Neto A.P.; Paiva L.C.; Pedro A.; Zabaglia S.

New psychosocial menopause instrument - a resource for coping and consulting
pp. 183-183(1)
Authors: Schultz-Zehden B.; Rosemeier H.P.

The natural history of the menopausal transition in Australian born women: an update from the Melbourne women's midlife health project
pp. 183-183(1)
Authors: Dudley E.; Guthrie J.; Hopper J.; Dennerstein L.

The Italian climacteric research group (ICARUS) study
pp. 183-183(1)
Authors: de Aloysio D.; Bacchi-Modena A.; Gambacciani M.; Meschia M.; Pansini F.; Peruzzi E.; Pisati R.

Psychosocial factors and attitude to menopause affecting menopause-related symptoms
pp. 184-184(1)
Authors: Barth-Olofsson A.S.; Collins A.

Clinical-epidemiological characteristics of two postmenopausal populations with different social-economical and educational levels
pp. 184-184(1)
Authors: Krakover R.; Depiano E.; Marquez N.; Perelstein S.; Ferreras M.E.; Benencia H.

Knowledge, attitude and practice of obstetrician and gynecologists in Taiwan towards menopause
pp. 184-184(1)
Authors: Yao B.L.; Hsu C.C.; Huang K.E.

Menopausal symptoms and psycho-social influences in family relationships
pp. 184-184(1)
Authors: Horiguchi F.; Ohta H.; Fuyuki T.; Sugimoto I.; Komukai S.; Makita K.; Takamatsu K.; Nozawa S.

The experience and knowledge of menopausal women in rural South Australia
pp. 185-185(1)
Author: Murtagh M.J.

Endometrium evaluation by microhysteroscopy study in climateric patients and its correlation by ultrasound study method
pp. 186-186(1)
Authors: Dotto J.E.; Vilarino A.; Ferrari A.; Tempone A.; Wittis S.; Vighi S.; Itala J.; Lema B.

Assessment of endometrial histology in women on tamoxifen therapy by ultrasonography
pp. 186-186(1)
Authors: Moskovic T.; Neskovic Z.; Runic S.; Labuda M.; Markovic A.; Lazic J.; Djukic M.; Bojovic M.

Effects of cyproterone acetate and medroxyprogesterone acetate on endometrial levels of IGF-IR and IGFBP-I in endometrial hyperplasia
pp. 186-186(1)
Authors: Baysal B.; Turfanda A.; Yalcin O.; Gulbaba R.G.; Buyukoren A.; Eserol F.; Akhan S.

Endometrial effects during long-term hormonal replacement therapy
pp. 186-186(1)
Authors: Spiewankiewicz B.; Stelmachow J.

Ultrasound screening in postmenopausal women
pp. 187-187(1)
Authors: Georgiev D.B.; Netzov V.; Chernev T.

A comparison of bleeding patterns with prempak C and transdermal estradiol and norethisterone acetate (Estracombi)
pp. 187-187(1)
Authors: Parsons A.D.; Rugby; Purdie D.W.; Hull; Sathanandan S.M.; Stirling; Sturdee D.W.; Solihull; Thompson W.

Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen: a transvaginal ultrasound study
pp. 187-187(1)
Authors: Fallo L.; Dordoni D.; Ruggeri C.; Palai N.; Omodei U.; Boccuti A.M.; Daldoss C.

Endometrial ultrasound transvaginal (TVU) assessment in postmenopausal women on hormone replacement therapy (HRT)
pp. 188-188(1)
Authors: Omodei U.; Ruggeri C.; Palai N.; Fallo L.; Boccuti A.M.; Dordoni D.

Histopathological findings of endometria on peri-menopausal uterine bleedings
pp. 188-188(1)
Authors: Kagabu T.; Matsuta M.; Nishiya I.

The morphological and biochemical response of the endometrium to two ''period-free'' hormone replacement therapy
pp. 188-188(1)
Authors: Okon M.; Lee S.; Laird S.; Li T.

Incidence of breakthrough bleeding after changing from cyclical HRT to tibolone
pp. 188-189(2)
Authors: Ahmed A.I.H.; Robinson J.; Rymer J.

Diagnostic assessment of postmenopausal uterine bleeding by outpatient hysteroscopy and endometrial sampling
pp. 189-189(1)
Authors: Benfatti M.; Grassini E.; Bosco P.; Iasi L.; Hanozet F.; Bertulessi C.

Sonographic findings of uterus and ovaries in normal pre and postmenopausal women
pp. 189-189(1)
Authors: Jirapinyo M.; Leelapattana P.; Theppisai U.; Krasaesub S.

The relation between dydrogesterone dosage and vaginal bleeding pattern in sequentially combined HRT
pp. 189-189(1)
Authors: van de Weijer P.; Barentsen R.; Kenemans P.

The bleeding patterns in three hormone replacement therapy (HRT) regimens: the effect of a hypo-oestrogenic state?
pp. 190-190(1)
Authors: Al-Azzawi F.; Bell S.C.; Habiba M.A.

Endometrial histology and the bleeding pattern of postmenopausal women on continuous combined HRT compared to tibolone
pp. 190-190(1)
Authors: Al-Azzawi F.; Habiba M.A.; Akkad A.A.; Phipps B.

Endometrial responses to a hormone replacement therapy (HRT) regimen: comparative histopathological assessment during the late ''pseudo-luteal'' phase
pp. 190-190(1)
Authors: Habiba M.A.; Bell S.C.; Deen S.; Al-Azzawi F.

Enhanced proliferation of endometrial stromal leukocytes during the late pseudoluteal phase of a hormone replacement therapy (HRT) regimen
pp. 190-190(1)
Authors: Habiba M.A.; Bell S.C.; Al-Azzawi F.

Hysteroscopic assessment: value in predicting abnormal uterine bleeding in perimenopausal women and bleeding on HRT
pp. 191-191(1)
Authors: Habiba M.A.; Akkad A.A.; Al-Azzawi F.

Oestrogen receptor and heat shock protein 27 expression during the late ''pseudo-luteal'' phase of a HRT regimen: adequate oestrogenic priming
pp. 191-191(1)
Authors: Bell S.C.; Habiba M.A.; Al-Azzawi F.

Progesterone receptor and Alpha-2-PEG/PEP/PP14 expression during the late ''pseudo-luteal'' phase of a HRT regimen-deficient glandular maturation?
pp. 191-191(1)
Authors: Bell S.C.; Habiba M.A.; Al-Azzawi F.

Bleeding pattern in two combined continuous hormone replacement therapy (HRT) regimes in climacteric women
pp. 191-191(1)
Authors: Campodonico I.; Valdivia I.

Interest of transvaginal color doppler ultrasonography (TCDU) in postmenopausal women prior hormone replacement therapy (HRT)
pp. 192-192(1)
Authors: Zenatti M.; Lafuma M.-P.; Guerin V.; Fachinetti C.; Alves L.; Barsi S.; Lopes P.

Comparison of endometrial evaluation by transvaginal ultrasonography (TVU) and endometrial biopsy in postmenopausal women
pp. 192-192(1)
Authors: Lopes P.; Zenatti M.; Cartier M.; Lecanuet S.; Delance V.; Bergeron C.; Ochsenbein E.; Guerin V.

Variation between pathologists in the reporting of endometrial histology with combination oestrogen/progestogen therapies
pp. 192-192(1)
Authors: Whitehead M.I.; Pickar J.

Long-term administration of tibolone is not associated with endometrial proliferation
pp. 193-193(1)
Authors: Kicovic P.; Rollason T.

Tibolone: dose-response analysis of uterine bleedings in a multicentre placebo-controlled study
pp. 193-193(1)
Authors: Kicovic P.; Empelen S.; Bennink H.C.

Bleeding rates-during a long-term placebo-controlled study with two doses of Tibolone
pp. 193-193(1)
Authors: Berning B.; Kicovic P.; Fauser B.; Bennink H.C.

Combined continuous hormonal replacement therapy (CC-HRT) influence of progestagen doses (PD) on bleeding (B) patterns of postmenopausal women (PW)
pp. 193-194(2)
Authors: Vidal D.R.; Martino M.; Paciocco M.; Aguirre M.; Deza E.G.; Mirkin A.

The effect of Tibolone (Livial) on uterine fibroids in postmenopausal women
pp. 194-194(1)
Authors: Gregoriou O.; Papadias C.; Konidaris S.; Vitoratos N.; Antonaki V.; Costomenos D.

Vaginal sonography of the endometrium in postmenopausal women on tilobone or low-dose estrogen treatment: a comparison
pp. 194-194(1)
Authors: Botsis D.; Kassanos D.; Kalogirou D.; Antoniou G.; Vitoratos N.; Antoniou D.

Transvaginal ultrasound and transvaginal hysterosonography (saline infusion) in the evaluation of the endometrium in fibroid uterus
pp. 194-194(1)
Authors: Surkont G.; Rubersz-Adamska G.; Suzin J.

The assessment of inter and intra observer variability in the measurement of endometrial depth by transvaginal ultrasound in healthy asymptomatic postmenopausal women
pp. 195-195(1)
Authors: Ballard P.A.; Tetlow R.; Turnbull L.; Mussurakis S.; Killick S.R.; Purdie D.W.

Activation of dormant abdominal wall endometriosis by hormone replacement therapy
pp. 195-195(1)
Authors: Hackman B.W.; Cooper J.C.; Schorr B.

Endometrial assessment of patients in menopause clinic
pp. 195-195(1)
Authors: Gokmen O.; Celikkanat H.; Gulerman C.; Moroy P.; Senoz S.; Oransay S.

Long-term effects of different hormone replacement therapy regimens on the endometrium
pp. 195-195(1)
Authors: Dogany M.; Celikkanat H.; Alaybeyoglu L.; Gulerman C.; Gokmen O.

Effects of tibolone on evolution of uterine fibroids in post menopausal women
pp. 196-196(1)
Authors: Wehba S.; Fernandes C.E.; Ferreira J.A.S.; Aldrighi J.M.; Baracat E.C.; Melo N.R.; Hegg R.

Effects of tibolone on endometrium and vagina in post menopausal women
pp. 196-196(1)
Authors: Wehba S.; Fernandes C.E.; Ferreira J.A.S.; Aldrighi J.M.; Baracat E.C.; Melo N.R.; Hegg R.

Endometrial safety during the sequential hormone replacement therapy
pp. 196-196(1)
Authors: Zaidieva Y.Z.; Smetnik V.P.; Ezhova L.S.

Endometrial histology and bleeding pattern during continuous HRT for one year
pp. 196-196(1)
Authors: Wollter-Svensson L.-O.; Jonasson A.; Granberg G.; Rymark P.; Tamsen L.

The effect of endometrium in postmenopausal women receiving hormone replacement therapy alternative to oral therapy
pp. 197-197(1)
Authors: Ottanelli S.; Becorpi A.; Bordonaro P.; Baldi S.; Lentini G.M.; Bruni V.

The effectiveness of hormone in relieving menopausal symptoms
pp. 198-198(1)
Authors: Panyakhamlerd K.; Limpaphayom K.; Taechakraichana N.

A comparison of self-rated and menstrually derived menopausal status
pp. 198-198(1)
Authors: Garamszegi C.; Dennerstein L.; Burger H.; Ryan M.; Guthrie J.; Dudley E.

Climacteric symptoms in a postmenopausal Czech population
pp. 198-198(1)
Authors: Nedstrand E.E.; Pertl J.; Hammar M.L.

Hormonal replacement therapy in postmenopausal ovarian insufficiency
pp. 199-199(1)
Authors: Ailamazyan E.K.; Nikanorova S.A.; Poteen V.V.; Rulev V.V.

Climacteric symptoms and nutritional status in japanese women
pp. 199-199(1)
Author: Sugiyama M.

Clinical experience with tibolone (livial)
pp. 199-199(1)
Author: Theppisai U.

A double-blind, placebo-controlled crossover study to determine the effects of a new 17B oestradiol transdermal matrix patch on climacteric symptoms in hysterectomised postmenopausal women
pp. 199-199(1)
Authors: Cooper A.; Ross D.; Spencer C.; Godfree V.; Colville N.; Whitehead M.

A study on premenopausal symptoms of Turkish women
pp. 200-200(1)
Authors: Oransay S.; Celikkanat H.; Moroy P.; Gulerman C.; Doganay M.; Ozaksit G.; Gokmen O.

Menopausal complaints: effect of the type of menopause
pp. 200-200(1)
Authors: Moroy P.; Celikkanat H.; Oransay S.; Gokmen O.; Doganay M.; Tan M.; Ozaksit G.

Clinical efficacy of percutaneous ERT and HRT in postmenopausal women
pp. 200-200(1)
Authors: Boschitsch E.; Wilfert H.

The estimation of kupperman's index by applying estracomb TTS preparation
pp. 200-200(1)
Authors: Ciszek V.; Poreba R.

Treatment of menopausal syndrome by beevenom and bee propolis (a new modality)
pp. 201-201(1)
Authors: Ali Farid A.; El Bambi M.; El Dali O.; Essia S.

The menopause rating scale (MRS II) - clusters of menopausal symptoms
pp. 201-201(1)
Authors: Schneider H.P.G.; Hauser G.A.

Oral testosterone - a viable alternative to injection or implant
pp. 202-202(1)
Author: Bartram D.H.

Efficacy and tolerability of two sizes of lyrelle 17E2 patch (25 cm² and 40 cm²) compared with estraderm TTS(R)50 in hysterectomised postmenopausal women
pp. 202-202(1)
Authors: van der Mooren M.J.; Rolland R.; Al-Azzawi F.; Hirvonen E.; Genazzani A.R.; Brincat M.P.

Clinical results of EP and P therapy in premenopausal women
pp. 202-202(1)
Authors: Marianowski L.; Grzechocinska B.

The effects of two different HRT regimens-oral and transdermal- on the Hungarian postmenopausal women
pp. 203-203(1)
Authors: Fulop V.; Dancso J.; Egyed J.

Post-marketing surveillance of transdermal estradiol + norethisterone (estracombi) in the United Kingdom
pp. 203-203(1)
Authors: Jones C.W.; Anstee J.R.; Bakshi R.

Preliminary data on ten years follow-up of patients on estradiol implants versus equine estrogens
pp. 203-203(1)
Authors: Dramusic V.; McCarthy T.; Goh V.H.H.; Annapoorna V.; Arulkumaran S.

Muscle/joint pains and vasomotor symptoms: two HRT regimens compared
pp. 203-203(1)
Authors: Oldenhave A.; Scholten P.C.; Euser R.; Boon J.

Well-being and vasomotor complaints: two HRT regimens compared
pp. 204-204(1)
Authors: Oldenhave A.; Scholten P.C.; Euser R.; Boon J.

Long term effects of cyclic-combined conjugated estrogens and dydrogesterone in the treatment of postmenopausal syndrome
pp. 204-204(1)
Authors: Gambacciani M.; Piaggesi L.; Cappagli B.; Ciaponi M.; Genazzani A.

Experiences with a new sequential hormone replacement therapy in perimenopausal women
pp. 204-204(1)
Author: Ernst U.

A comparative study of progesterone (P) pharmacokinetics following administration of crinone(R) and utrogestan(R) (UT) to healthy postmenopausal women
pp. 204-205(2)
Authors: Levine H.L.; Watson N.

Effect of estrogen replacement on functioning ovaries after hysterectomy
pp. 205-205(1)
Authors: Eicher W.; Kuckatz C.; Mueck A.

Clinical, lipoprotein and mammographic changes in climacteric women treated with two combined continuous (CC) hormone replacement therapy (HRT) regimes.
pp. 205-205(1)
Authors: Valdivia I.; Campodonico I.

A new second generation transdermal drug delivery system for HRT: mechanism of action
pp. 205-205(1)
Authors: Rohr U.D.; Nauert C.

A study of the effect of transdermal opposed HRT therapy (Femapak 80) on flushing, endometrium and lipid profile
pp. 206-206(1)
Author: Cogswell D.

The UK Kliogest (Kliofem) multicentre study: organisation and design
pp. 206-206(1)
Author: Barlow D.

Randomised double-blind endometrial study of a vaginal progesterone gel in oestrogen-treated postmenopausal women.
pp. 206-206(1)
Authors: Ross D.; Pryse-Davies J.; Collins W.; Whitehead M.

A retrospective assessment of sixteen years experience with oestrogel in three specialist menopause clinics
pp. 207-207(1)
Authors: Colville N.; Morris K.; Ross D.; Godfree V.; Cooper A.; Spencer C.; Whitehead M.

Percutaneous micronized progesterone pharmacocinetic
pp. 207-207(1)
Authors: Valls-Llobet C.; Borras G.; Fuentes M.; Backstrom T.

Differences in lipids and bleeding patterns between 2 types of hormonal replacement therapy = a sequential versus a continuous combined hormonal replacement
pp. 207-207(1)
Authors: Yu S.; Chin Y.; Lim B.; Sim M.

A 25% difference in E2 concentrations contained in a matrix-type patch, does not affect the daily E2 release
pp. 208-208(1)
Authors: Rocher I.; Donazzolo Y.; Collette J.; Jochemsen R.; Reginster J.; Tsouderos Y.

Pharmacokinetics of estradiol blood content obtained with S21102, a new 7-day patch
pp. 208-208(1)
Authors: Lhote O.; Rocher I.; Jochemsen R.; Tsouderos Y.

Efficacy and tolerability of the 7-day transdermal estradiol patch S21102 in the treatment of postmenopausal symptoms
pp. 208-208(1)
Authors: Pelissier C.; Maller A.; Agogue M.; Renaud M.; Breil M.; Grimard A.; Rocher I.; Tsouderos Y.

25mg oestradiol implants and 1mg norethisterone as continuous combined HRT in the over 60's
pp. 208-209(2)
Authors: Panay N.; Studd J.W.W.; Sands R.; Zamblera D.

An open, randomized assessment of the efficacy and safety of two transdermal estradiol patches for relief of climacteric symptoms
pp. 209-209(1)
Authors: Baracat E.; Aguiar L.F.; Barbosa I.C.; Campos A.A.; Haidar M.; Leal M.J.W.C.B.; de Lima G.R.; Sa M.F.; Soares A.; Wehba S.; Siseles N.; Porcile A.

Hormonal replacement therapy (HRT). Evaluation of a novel 25 days regimen with percutaneous estradiol(PE2) and micronized oral progesterone(MP)
pp. 209-209(1)
Authors: Marengo M.; Vidal D.R.; Deza E.G.

Efficacy of tibolone during early menopause and postmenopause
pp. 210-210(1)
Author: Lugones L.

Five year experience with hormone replacement therapy
pp. 210-210(1)
Authors: Magyar Z.; Szendei G.; Toth K.S.; Papp Z.

Severe mesenterial thrombosis can be a complication of continuously applied oestrogen and gestogen therapy
pp. 210-210(1)
Authors: Szendei G.; Peter A.; Magyar Z.; Perner F.; Papp Z.

Use of a levonorgestrel releasing intrauterine device in substitutive estrogenic therapy in menopause
pp. 211-211(1)
Authors: Becorpi A.; Toni F.; Bordonaro P.; Barzagli M.; Tantini C.; Ottanelli S.

Transdermal estradiol replacement using chlor-madinone acetate as sequential progestogen
pp. 211-211(1)
Authors: Mueck A.O.; Melchert F.; Deuringer F.-U.; Roemer T.; Seeger H.; Lippert T.H.

Treatment with testosteronundecanoate in postmenopausal women - a pharmacological study
pp. 211-211(1)
Authors: Floter A.; Nathorst-Boos J.; Carlstrom K.; von Schoultz B.

Management of the menopause with continuous HRT
pp. 211-211(1)
Authors: Signorile P.; Angeli R.A.; Ronca S.; Bechini F.; Plotti G.

A two-year study with low dose, continuous, unopposed esterified estrogens: prevention of postmenopausal bone loss with minimal endometrial effects
pp. 212-212(1)
Authors: Lucas J.; Rebar R.; Speroff L.; Trabal J.; Silfen S.; van der Hoop R.G.; Wiita B.

Menopausal women treated with livial
pp. 212-212(1)
Authors: Serebrennikova K.G.; Pimensva L.J.

Phytoestrogens - the alternative approach
pp. 213-213(1)
Authors: Georgiev D.B.; Iordanova E.

Effects of ApoEphenotype on lipids, fat rates and climacteric symptoms
pp. 213-213(1)
Authors: Somekawa Y.; Yorimitsu A.

The measurement of urinary isoflavone levels by high-performance liquid chromatographic assay in Chinese menopausal women
pp. 213-213(1)
Authors: Roach V.; Chung T.; Hjelm N.; Haines C.

Soy and hot flushes
pp. 213-213(1)
Authors: Pansini F.; Albertazzi P.; Bonaccorsi G.; Zanotti L.; Campobasso C.; Negri C.; de Aloysio D.; Mollica G.; Bottiglioni F.

The effect of coumestrol and zearalanol on bone loss in the oophorectomized rat
pp. 214-214(1)
Authors: Draper C.R.; Dick I.M.; Edel M.; Prince R.L.

Effect of supplemental isoflavones on noninvasive haemodynamics in postmenopausal women
pp. 214-214(1)
Authors: Hayward C.S.; Knight D.C.; Eden J.A.; Kelly R.P.

Effects of dietary phytoestrogens in postmenopausal women
pp. 214-214(1)
Authors: Dalais F.S.; Rice G.E.; Murkies A.L.; Bell R.J.; Wahlqvist M.L.

Chinese herbal medicine-a treatment for perimenopausal hot flushes?
pp. 214-214(1)
Author: Beer S.L.

The alternative treatment seeker-who wishes to avoid hormone replacement therapy and why?
pp. 215-215(1)
Author: Beer S.L.

Extract of Cimicifuga racemosa in the treatment of neurovegetative symptoms in women in the perimenopausal period
pp. 215-215(1)
Author: Mielnik J.

Clinical evaluation of non-hormonal drug 'minofil' in the management of post menopausal syndrome
pp. 215-215(1)
Author: Nanda U.K.

The effect of isoflavones on menopausal symptoms
pp. 215-215(1)
Authors: Eden J.; Knight D.; Howes J.; Kelly G.

Climacterium virile - influenced in pesticide applicators
pp. 216-216(1)
Authors: Straube E.; Straube W.; Kruger E.; Bradatsch M.; Meisel M.

Estradiol-17 - a reasonable hormone replacement for the aging male?
pp. 216-216(1)
Authors: Schroder J.; Kaufmann G.; Oettel M.; Romer W.; Sobek L.

Treatment of keratoconjunctivitis sicca during menopause with topical 17--estradiol in comparison with a tear substitute
pp. 216-216(1)
Authors: Sator M.O.; Gruber D.M.; Golaszewski T.L.; Frigo P.G.; Hommer A.F.; Fischl F.H.; Huber J.C.

The influence of hormone therapy of the intraocular pressure in menopausal women
pp. 216-216(1)
Authors: Sator M.O.; Gruber D.M.; Hommer A.F.; Frigo P.G.; Fischl F.H.; Huber J.C.

Case report: monozygotic twin, one of which was anencephalic in a climacteric patient
pp. 217-217(1)
Author: Jeri A.R.

Disease risks for long term users of hormone replacement therapy
pp. 217-217(1)
Authors: Geelhoed E.A.; Prince R.L.

Radiation accelerates the onset of menopause
pp. 217-217(1)
Authors: Soda M.; Akahoshi M.; Cologne J.; Izumi S.

Pregnancy outcome in ovum donation cycles
pp. 218-218(1)
Authors: Irvine R.; Billett A.; Korea L.; Abdalla H.; Studd J.W.

ZIFT versus et in a randomised assessor blind trial in ovuum donation cycles
pp. 218-218(1)
Authors: Irvine R.; Korea L.; Billett A.; Abdalla H.; Studd J.W.

Age at menopause: the effect of leimyoma uteri
pp. 218-218(1)
Authors: Gokmen O.; Moroy P.; Gulerman C.; Celikkanat H.; Senoz S.; Sener B.

Pregnancies in premenopausal women
pp. 218-218(1)
Authors: Maas D.H.A.; Nobakht N.

The role of routine ultrasound in assistance of postmenopausal women with emphasis on adnexal mass
pp. 219-219(1)
Authors: Pedro A.; Pinto Neto A.; Costa Paiva L.; Zabaglia S.; Salinas J.; Masetto D.; Dantas F.

Screening of asymptomatic ovarian, masses in post menopausal women
pp. 219-219(1)
Authors: Sener A.B.; Kuscu E.; Seckin N.C.; Ozaksit G.; Gokmen O.; Ekici E.; Celikkanat H.

Myoma uteri significantly delays the age at menopause
pp. 219-219(1)
Author: Tamada T.

Assessing post menopausal status after hysterectomy
pp. 220-220(1)
Authors: Everett M.; Hardicre M.; Hay A.; Westmacott C.; Towers H.; Drife J.; Smith M.

Hysteroscopic resection of benign intrauterine lesions in post-menopausal women
pp. 220-220(1)
Authors: Grassini E.; Benfatti M.; Bertulessi C.; Iasi L.; Radici G.; Capetta P.

Tubal ligation and long term health outcomes: retrospective information in the Melbourne women's midlife study
pp. 220-220(1)
Authors: Taffe J.R.; Dudley E.C.; Dennerstein L.

Compliance to estrogen treatment after hysterectomy and bilateral oophorectomy, patients lifestyle and knowledge of HRT effects
pp. 220-220(1)
Author: Hee P.